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Músculo esquelético, caquexia, cancro, mitocondria, cardiolipina, 
fosforilação oxidativa. 
 
A caquexia associada ao cancro é uma condição fisiopatológica 
complexa caraterizada por acentuada perda de massa 
muscular.Recentemente, esta situação foi associada à disfunção 
mitocondrial. A relação e o papel do proteoma e lipidoma mitocondrial 
e a funcionalidade deste organelo permanece pouco compreendida, 
em particular no contexto do catabolismo muscular associado ao 
cancro. No sentido de melhor compreender os mecanismos 
moleculares subjacentes às alterações no músculo esquelético na 
caquexia associada ao cancro, utilizaram-se 23 ratos Wistar divididos 
aleatoriamente em dois grupos: com cancro da bexiga induzido pela 
exposição durante 20 semanas a N-butil-N-(4-hidroxibutil)-
nitrosamina (grupo BBN, n=13) ou saudáveis (CONT, n=10). No final 
do protocolo verificou-se que os animais do grupo BBN 
apresentavam uma perda significativa de peso corporal e de massa 
muscular. Também foi observado uma diminuição da atividade da 
fosforilação oxidativa de mitocôndrias isoladas do músculo 
gastrocnemius.  a qual foi acompanhada por alterações do perfil de 
fosfolípidos (PL) da mitocôndria. A alteração do lipidoma mitocondrial 
caraterizou-se pelo aumento do teor relativo de fosfatidilcolinas (PC) 
e fosfatidilserina (PS) e uma redução no teor relativo de cardiolipina 
(CL), ácido fosfatídico (PA), fosfatidilglicerol (PG) e fosfatidilinositol 
(PI). A análise realizada por GC-FID e HPLC-ESI-MS evidenciou 
ainda um aumento de ácidos gordos polinsaturados, com um 
aumento destacado de C22:6 em PC, PE e PS. A diminuição de CL  
foi acompanhada por diminuição na expressão de citocromo c e 
aumento da razão Bax/Bcl2, sugestivo de maior suscetibilidade à 
apoptose e stress oxidativo. Embora em níveis mais elevados, a 
UCP-3 não parece proteger as proteínas mitocondriais da lesão 
oxidativa atendendo ao aumento do teor de proteínas carboniladas. 
Em conclusão, a remodelação de PL da mitocôndria parece estar 
associada à disfunção da OXPHOS e, consequentemente, do 
catabolismo muscular associado ao cancro. 
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Cancer cachexia (CC) is a complex pathophysiological condition 
characterized by a marked muscle wasting. Recently, this situation has 
been associated to mitochondrial dysfunction. The interplay and role of 
mitochondrial proteome and lipidome and also the functionality of this 
organelle remains poorly understood in the context of cancer-related 
muscle wasting. To better understand the molecular mechanisms 
underlying skeletal muscle wasting, 23 Wistar rats were randomly 
divided in two groups: animals with bladder cancer induced by the 
exposition to N-butyl-N-(4-hydroxybutyl)-nitrosamine for 20 weeks 
(BBN, n=13) or healthy ones (CONT, n=10). At the end of the 
experimental protocol, BBN animals demonstrated a significant body 
weight and muscle mass loss and was also observed an decreased 
activity of oxidative phosphorylation in mitochondria isolated from 
gastrocnemius muscle, which was accompanied by alterations of this 
organelle’s phospholipids (PL) profile. The mitochondrial lipidome 
alterations were characterized by an increase of the relative content of 
phosphatidylcholines (PC) and phosphatidylserine (PS) and a decrease 
of cardiolipin (CL), phosphatidic acid (PA), phosphatidylglycerol (PG) 
and phosphatidylinositol (PI). GC-FID and HPLC-ESI-MS analysis also 
showed an increase of polyunsaturated fatty acids, particularly of C22:6 
in PC, PE and PS. The observed decrease in CL class was 
accompanied by a decrease in the expression of cytochrome c, and an 
increase of the ratio Bax/Bcl-2, suggestive of a greater susceptibility to 
apoptosis and oxidative stress. Although in higher levels, UCP-3 does 
not seem to protect mitochondrial proteins from oxidative damage 
considering the increased content of carbonylated protein. In 
conclusion, the PL remodeling seems to be associated to OXPHOS 
dysfunction and consequently to muscle catabolism associated with 
cancer. 
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I. Introduction 
 
 Cancer is a major health concern and the worldwide leading cause of morbidity 
and mortality [1]. Deaths from cancer are expected to increase, with an estimated 13.1 
million deaths in 2030 [1]. The majority of patients with advanced cancer undergo 
involuntary loss of weight usually denominated as cachexia [2, 3]. Due the high incidence 
of cancer cachexia, more research should be developed aiming to better understand the 
underlying molecular mechanisms and, ideally, develop measures to prevent muscle 
wasting, and so improve patients’ quality of life. 
 Cachexia, derived from the Greek kakos and hexis–“bad condition” is a wasting 
syndrome characterized by progressive loss of muscle with or without loss of fat mass [4]. 
This condition is observed in many diseases such as cancer, chronic heart failure, and 
chronic obstructive pulmonary disease (COPD), and is estimated to be responsible for the 
deaths of 22% of cancer patients [2, 4-13]. Cancer cachexia (CC) also seems to be 
responsible for a decreased response to chemotherapy leading to death when the weight 
loss is higher than 30% [7, 10, 14, 15].  The most prominent phenotypic feature of cancer 
cachexia is muscle wasting and once skeletal muscle comprise more than 40% of the body 
weight [4, 16, 17], its wasting contributes to  increased disability, fatigue, poor quality of 
life, and increased mortality in cancer  patients [2, 6, 7, 10, 15-17]. Among the cellular 
mechanisms underlying muscle wasting, the imbalance between protein synthesis and 
degradation towards increased proteolysis has been suggested as one of the most relevant 
processes involved in the pathogenesis of cancer-related cachexia [2, 10]. The involvement 
of mitochondrial dysfunction in skeletal muscle wasting was recently reported [18-21]. 
However, the underlying molecular mechanisms centered on mitochondria are not well 
elucidated.   
1.1. Cancer cachexia pathophysiology 
 
Cancer cachexia is a complex metabolic syndrome underlying illness and 
characterized by a marked weight loss in adults or growth failure in children [3, 4]. 
Anorexia, inflammation, insulin resistance and increased muscle protein breakdown are 
frequently related with wasting disease [4].  
Asthenia or lack of muscular strength is one of the most prominent symptoms and 
reflects the muscle wasting [10, 12, 17]. Indeed, muscle wasting has been reported as an 
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important feature in the pathophysiology of cachexia and a major cause of fatigue in 
patients [22-24]. Several studies on cachexia suggest the importance of the inflammatory 
response characterized by increased levels of pro-inflammatory cytokines, acute phase 
proteins and metabolic disturbances such as glucose intolerance, anemia, low levels of 
plasmatic albumin, among others [4]. Body weight loss is by far the most important 
parameter required to define the cachexia score in patients with cancer [4].  Besides 
whole body and lean body mass loss, catabolic drivers (including the ones involved in 
immune and inflammatory response) are important to predict how CC will affect patient’s 
quality of life, and physical performance  [4]. Imunosupression response accounts for up 
to 20% and might be an early marker of cachexia [4]. Besides immune disturbance, 
metabolic alterations have been considered to result from a variety of interactions 
between the host and the tumor in cancer cachexia (Figure 1) [7, 25-27], mediated by 
tumor-derived pro-inflammatory cytokines. Systemic inflammation initiates with the 
induction of the acute phase response and the mobilization of fat reserves, which together 
with pro-cachectic factors secreted by the tumor, promotes waste of muscular tissue and 
fat stores [25]. However, it is not certain whether the tumor cell production of pro-
inflammatory cytokines or the host inflammatory cell response is the primary cause of 
cachexia [7].   
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Figure 1: Pathophysiological changes underlying cancer cachexia [adapted from 26, 27]. 
 
 
1.2. Mediators of cancer cachexia 
 
 The mediators of cachexia are associated with both waste of fat tissue and 
muscular tissue and can be divided into two categories:  
(i) host factors, such as tumor necrosis factor-α (TNF- α), interleukin-1 (IL-1), 
interleukin-6 (IL-6) and interferon-γ (IFN-γ); (ii) tumor factors that have a direct 
catabolic effect on host tissues, such as lipid-mobilizing factor (LMF), which acts on 
adipose tissue, and proteolysis-inducing factor (PIF), which acts on skeletal muscle [17, 
26]. Pro-inflammatory cytokines were associated with a significant loss of skeletal 
muscle mass in mice bearing MAC16 adenocarcinoma and mice bearing cell lines 
(JHU022, JHU012) [28, 29]. TNF-α is a cytokine primarily produced by macrophages 
responsible for the stimulation of the NF-κB pathway, which is involved in cytokine 
mediated proteolysis [2, 10, 30], and has been correlated with the increase of ubiquitin 
gene expression in rat soleus muscle [31]. The involvement of this cytokine in the 
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induction of cachexia appears to vary with tumor type and each may rely on the 
concomitant production of other cytokines or factors responsible for the cachexia [12].  
 
Furthermore, TNF-α and the tumor factor PIF have been suggested as the major inducers 
of skeletal muscle atrophy in cachectic patients through the activation of the ubiquitin-
proteasome pathway (UPP) [2, 7]. PIF mediates catabolism in animals bearing tumors 
presenting muscle loss as in mice bearing MAC16, being absent in animals bearing 
tumors but with no evidences of cachexia [23, 32]. Since PIF is expressed in tumors and 
correlates with weight loss, it is likely to be associated with cancer-related cachexia [33, 
34].  Interleukin-6 (IL-6) has a major role in the inflammatory process and has been 
suggested to induce cachexia in mice by increasing tumor burden and protein degradation 
in muscle through the activation of proteolytic pathways [2]. The association between IL-
6 and cancer cachexia was confirmed with the administration of an anti-mouse IL-6 
antibody to murine colon adrenocarcinoma tumor-bearing mice that reversed key 
parameters of cachexia [2]. Another cytokine that has been proposed to play a role in 
cancer cachexia is IFN-γ, which is produced by activated T and NK cells and its 
biological activities overlap with those of TNF-α [2, 27, 30]. Nevertheless, no significant 
correlation between IFN-γ serum levels and weight loss was observed in CC patients 
though the administration of a monoclonal antibody against this cytokine  reversed the 
wasting syndrome induced by Lewis lung carcinoma in mice [2, 30, 35]. Another 
mediator implicated in CC-related fat loss is the lipid-mobilizing factor (LMF) through 
increased lipolysis [2, 7, 9, 15]. Loss of adipose tissue occurs more rapidly than lean 
tissue with the progression of cancer cachexia [2]. Despite the association with cancer 
cachexia, fat tissue wasting is not well defined [24], being skeletal muscle protein 
degradation the main cause of weight loss [36, 37]. Moreover, in a study performed with 
animal models submitted to fasting-refeeding periods it was observed an increased 
protein degradation in normal rats but not in tumor bearing rats, suggesting that muscle 
wasting occurs despite of the fed state [38].  
2. Mechanisms underlying cancer-related skeletal muscle wasting 
 
 CC-related muscle wasting has been associated with increased proteolysis, 
decreased protein synthesis, or a combination of these two cellular processes. Protein 
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degradation has been suggested to be the major cause of skeletal muscle loss, and involves 
cellular mechanisms activated by mediators such as TNF-α and PIF [7, 10, 17, 39]. 
 The skeletal muscle contains several proteolytic systems, two of which have been 
suggested to play a major role in cancer-related skeletal muscle wasting [40]. These 
include the non-lysosomal calcium (Ca
2+
)–dependent protease system and the ATP-
dependent ubiquitin-proteasome pathway [37, 41]. The non-lysosomal Ca
2+
-dependent 
protease system consists of a family of Ca
2+
-activated cysteine proteases known as 
calpains. These proteases are activated by an increase in cytosolic calcium, suggestive of 
injury [30, 42]. Calpains degrade the structures that keep myofibrillar proteins assembled 
in the myofibrils, acting as initiators of myofibrillar protein degradation [12]. In fact, 
increased calpains levels were observed in the skeletal muscle of cachectic tumor-bearing 
rats [43]. 
 The ubiquitin-proteasome pathway is the main catabolic system involved in 
cancer-related increase of muscle degradation [7, 28].  UPP is activated in catabolic states 
resulting in muscle atrophy [30]. The major function of the UPP is tagging damaged 
proteins with a small protein called ubiquitin. The ubiquitinated proteins then enter the S26 
proteasome, which breaks them into small peptides [10, 42, 44]. In normal states, the UPP 
degrades damaged and defective proteins produced by errors in gene transcription, mRNA 
translation, or oxidative stressors [12]. However, in disease states such as cancer, the 
activity of the UPP increases, leading to accelerated ubiquitination and subsequent 
degradation of proteins. Ubiquitination is performed by the action of several enzymes: 
ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and an ubiquitin 
ligase (E3). Two muscle-speciﬁc ubiquitin ligases, muscle ringer ﬁnger 1 (MuRF1) and 
muscle atrophy F-box (MAFbx) also called atrogin-1, have been suggested as key 
regulators of skeletal muscle proteolysis under catabolic conditions [45, 46]. 
 In tumor-bearing animals, increased expression of the UPP in skeletal muscle was 
associated with a subsequent increased rate of muscle protein degradation [23, 44]. 
Moreover, ATP depletion decreases protein degradation in cachectic tumor-bearing rats, 
supporting the theory that the ATP-dependent Ub-proteasome pathway is primarily 
responsible for skeletal muscle degradation [30, 37]. CC-related muscle wasting also relies 
on impaired protein synthesis in skeletal muscle through the Akt pathway, a key signaling 
mechanism that regulates muscle mass. The two main branches of this pathway are the 
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Akt/mTOR pathway which controls protein synthesis, and the Akt/FOXO pathway which 
controls protein degradation [47, 48]. Decrease of Akt-dependent signaling in human 
skeletal muscle has been associated with CC [49]. The mammalian target of rapamycin 
(mTOR) is a protein that is activated under specific conditions, and its downstream 
mediators enable the efficiency of translation [50]. Akt is a member of the 
phosphatidylinositol 3-kinase (PI3K) pathway [51], corresponding to an upstream 
regulator of mTOR, and plays a central role in integrating anabolic and catabolic 
responses. mTOR phosphorylation, and subsequently phosphorylation of its downstream 
targets leads to increased protein synthesis [46, 49]. This kinase is also involved in cellular 
stress and apoptotic signaling, through the control of the forkhead box protein O (FOXO) 
1 and FOXO3 transcription factors (Figure 2) [51, 52]. 
 
 
 
Figure 2: Schematic representation of the Akt/mTOR and Akt/FOXO pathways in anabolic (A) and 
catabolic conditions (B). P phosphorylation, activation or inactivation; PI3K phosphatidylinositol 3-kinase; 
Akt protein kinase B; FOXO forkhead protein box O; AMPK AMP-activated kinase; 4E-BP1 eIF4E-
binding protein 1; S6K1 S6 kinase; MAFbx muscle atrophy F-box; MuRF1 muscle ringer ﬁnger 1 [adapted 
from 51, 52, 53].  
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 Evidences suggest that impaired signaling Akt pathway may be involved in the 
suppression of protein synthesis and induction of protein degradation in catabolic 
conditions [54]. In fact, a study demonstrated that Akt in skeletal muscle of cancer 
cachectic patients is reduced by almost 55% relatively to levels in skeletal muscle from 
normal patients [49].   
3. The role of mitochondria in muscle wasting  
3.1. Mitochondrial dysfunction in wasting conditions 
 
  Mitochondrion is an intracellular organelle found in most eukaryote cells and 
plays an important role in cellular ATP production, in the regulation of cell death by 
apoptosis, in the synthesis of key metabolites for protein synthesis, pyruvate oxidation and 
oxidation of fatty acids, calcium buffering and homeostasis [55-57]. This cross talk 
between cell and mitochondria might leads to cell adaptation to physiological changes or 
the cell death. The ATP production occurs mainly from glucose and fatty acid oxidation 
and to a lesser extension from amino acid oxidation. The acetyl-CoA resultant from β-
oxidation pathway enters in the Krebs cycle and is used in ATP generation. Both oxidative 
pathways are related to the mitochondrial electron transport chain (ETC), whose protein 
content and activity, such as cytochrome c oxidase, define the mitochondrial oxidative 
capacity. Electrons generated in the Krebs cycle from the oxidation of acetyl-CoA are 
carried from reduced nicotinamide adenine dinucleotide (NADH) and succinate to complex 
I (NADH dehydrogenase) and complex II (succinate dehydrogenase), providing the 
electron transport chain. The ETC is located into the mitochondrial inner membrane and 
consists of complexes I-IV, containing electron carriers such as coenzyme Q or 
ubiquinone, and cytochrome c, which transport the electrons from one complex to the next 
with oxygen acting as the final electron acceptor. In this process of electron transport is 
generated an electrochemical gradient that provides the energy required to drive the 
synthesis of ATP by complex V, ATP synthase (Figure 3). This electrochemical gradient 
states the coupling between oxidative and phosphorylative reactions, corresponding to 
oxidative phosphorylation (OXPHOS) [58, 59]. The utilization of fatty acids as an energy 
source requires the optimal functionality of the mitochondrial electron chain and 
OXPHOS. NADH is involved into the electron transport chain at complex I and electrons 
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are transferred from acyl CoA dehydrogenases via the electron-transfer flavoprotein (ETF), 
ETF dehydrogenase and ubiquinone to complex III as depicted in Figure 3. Deficiencies in 
the ETF pathway lead to impaired fatty acid oxidation [60]. 
 
 
Figure 3: Representation of the electron transport chain with the protein complexes and their substrates in 
relation with the inner mitochondrial membrane. Complex I (NADH dehydrogenase); complex II (succinate 
dehydrogenase); complex III (ubiquinone cytochrome c oxireductase); complex IV (cytochrome oxidase), 
complex V (ATP synthase); NDi and NDe, internal and external alternative NAD(P)H dehydrogenases; 
AOX, alternative oxidase; GP, glycerol-3-phosphate; ETF, electron transfer flavoprotein; DHO, 
dihydroorotate; CoQ, Coenzyme Q; C, cytochrome c [adapted from 59]. 
 
  Mitochondria generate more than 90% of cell energy by OXPHOS, which occurs 
in the inner mitochondrial membrane and converts reducing equivalents and oxygen into 
energy and water [61]. This organelle is also a primary source of endogenous reactive 
oxygen species (ROS), which are byproducts of OXPHOS activity [55, 56]. Indeed, from 
the oxygen utilized by the mitochondria during respiration, 0.4-4.0 % is converted in 
superoxide radical (O2
•-
), and when its production overwhelm the antioxidant capacity 
oxidative damage of biomolecules occurs [61, 62]. Complexes I and III are the principle 
sites of ROS and are at the same time its main targets, together with ATP synthase [61, 63, 
64]. Regarding  mitochondrial lipids, these are predominantly phospholipids, being 
phosphatidylcholine, phosphatidylethanolamine and cardiolipin the most representative 
classes [67]. Increased ROS production and mitochondrial dysfunction have been 
associated with oxidative damage of mitochondrial phospholipids [63, 65, 66]. 
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  The deregulation of mitochondrial function has been implicated in 
pathophysiological conditions as CC, since is directly related to decreased muscle 
oxidative capacity [68]. Furthermore, the mitochondrial dysfunction in the skeletal muscle 
with a consequent diminished oxidative phosphorylation efficiency and impaired 
mitochondrial dynamics has also been associated with systemic inflammation and skeletal 
muscle wasting [68]. Indeed, the activation of TNF-α-induced NFB was shown to 
decrease the activity of regulators involved in mitochondrial biogenesis and affect 
downstream oxidative proteins, leading to impaired muscle oxidative capacity [69]. 
The dysfunction of this organelle can lead to a cascade of events whereby mitochondrial 
damage causes additional damage [70]. The reduced ATP synthesis, suggestive of 
mitochondrial bioenergetics dysfunction, ultimately leads to skeletal muscle wasting [21]. 
Several studies have described changes in mitochondria shape, number, and function in 
wasted skeletal muscle [19, 20, 71]. Gastrocnemius muscle from tumor-bearing mice was 
found to have an abnormally low mitochondrial respiratory chain activity, and indirect 
evidence also suggests that the mitochondrial oxidative energy metabolism may be 
compromised relatively early in the wasting process [20, 71]. In the control of energy 
metabolism,  mitochondrial uncoupling proteins (UCPs) assume an important role, once 
the uncoupling of oxidative phosphorylation leads to decreased ATP synthesis rate [2, 17, 
72]. In skeletal muscle UCP-3  overexpression was related to cancer cachexia in animal 
models [21, 72-74]. Moreover, upregulation of UCP3 has been associated with the 
activation of proteolytic pathways in wasted muscle [75]. 
  Ushmorov et al. [71] studied the mitochondrial oxidative phosphorylation from 
gastrocnemius muscle of C57/BL6 mice bearing the fibrosarcoma MCA-105 and observed 
a reduction of 25% in mitochondria oxygen consumption. This study highlighted a 
reduction in complex IV activity in skeletal muscle of cachectic mice, which was reverted 
by supplementation with cysteine and ornithine [71]. By modulating ROS production at 
mitochondria, pro-inflammatory cytokines such as IL-1, IL-6, TNF-α, and IFN-γ, promotes 
muscle wasting [76]. Indeed, it was reported  that TNF- α inhibits the mitochondrial ETC 
in different cell lines [77]. Nevertheless, the role of these cytokines in CC-related skeletal 
muscle mitochondrial dysfunction was not yet demonstrated. 
  In overall, despite being the most powerful intracellular source of ROS, 
mitochondria are also a primary target for the oxidative damage. The biomolecules that are 
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particularly susceptibility to ROS include lipids, proteins from the oxidative 
phosphorylation and mtDNA. The oxidative modification of these molecules leads to 
impaired function of mitochondria and impacts cell viability [65, 66]. Thus, it seems 
particularly important to explore the structural changes promoted by ROS in mitochondrial 
biomolecules and their relevance in wasted muscle. 
 
3.1.1. Biomolecular alterations underlying muscle wasting-related mitochondrial 
dysfunction 
 
 Among the main targets of ROS in mitochondria are the membrane lipids, the 
OXPHOS complexes proteins from metabolic pathways, and mtDNA (Figure 4) [61, 78]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Sources of reactive oxygen species and their main targets of reactive oxygen species [adapted 
from 78]. 
 
Membrane phospholipids are essential for mitochondria integrity and functionality 
since they can impact electron transport chain activity, mitochondrial protein import, 
membrane fluidity and permeability, and ultimately ATP synthesis [79]. Given the nearly 
absent variation in the mitochondrial phospholipid composition among different cells is 
supposed that great changes cannot be tolerated. Indeed, alterations in phospholipid 
content and also phospholipid damage have been linked to several pathological disorders 
[80]. The main phospholipid targets of peroxidation are not fully defined [81]. However, 
mitochondrial lipid peroxidation products led to impaired barrier function of membranes 
by interacting with proteins and/or with the lipid moieties of the membrane [82]. It is well 
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known that the anionic phospholipid cardiolipin (CL) has been suggested as a particularly 
susceptible PL in mitochondria [83, 84]. Lipids with a high degree of unsaturation are 
more susceptible to oxidation and cardiolipin contains a higher ratio of unsaturated to 
saturated fatty acid residues compared with the other phospholipids of the inner 
mitochondrial membrane [65].  In fact, loss of CL content is the most commonly reported 
pathological alteration of the CL profile. A selective loss of CL content could occur due to 
CL degradation, decreased CL synthesis resulting from impaired function of enzymes 
involved or decreased availability of CL precursors such as phosphatidylglycerol [80]. This 
CL loss, together with alterations in its acyl chain composition and/or CL peroxidation 
have been associated with mitochondria dysfunction, being responsible for alterations in 
the stability of mitochondrial membranes, increased permeability and decreased 
mitochondrial respiratory rate [80, 85]. Indeed, disorders underlying mitochondrial 
dysfunction associated with the inhibition of catalytic activity due to the loss of CL have 
been described for both complexes III and IV [80]. The identification and characterization 
of oxidized cardiolipin was also achieved using a combination of thin layer 
chromatography and electrospray ionization/mass spectrometry (ESI-MS) [84, 86]. Though 
in low levels in the inner membrane of mitochondria, phosphatidylglycerol (PG) 
accumulates in mitochondria when CL synthesis is decreased, partially compensating some 
functions of CL [87]. Moreover, similarly to CL, PG also seems to affect electron transfer 
efficiency and mitochondrial respiratory rate since its proximity to O2 transfer pathway and 
PG’s contribution in the stabilization of the complex IV [88].  
Besides, injury to mitochondria induced by lipid peroxidation can lead to additional 
ROS production and be associated with mitochondrial dysfunction [81]. Regarding this 
lipid-oxidative damage, the uncoupling protein UCP-3 has been proposed to be involved in 
the protection of lipids from oxidative damage [89]. In fact, uncoupling of mitochondrial 
respiratory chain is related to decreased ROS production [90].  
The oxidative damage of proteins generally leads to its loss of function [66]. Free radicals 
can directly induce the detachment of the pro-apoptotic factor cytochrome c from the inner 
mitochondrial membrane into the cytosol [91]. Indeed, mitochondrially-generated ROS has 
been shown to decrease the content of cardiolipin in the membrane, which interaction is 
required for cytochrome c attachment and an efficient respiratory activity [80, 85].  This 
release interrupts the transfer of electrons between ETC complexes III and IV, leading to 
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radical species production that could accelerate apoptotic processes [92]. In fact, the 
release of cytochrome c from mitochondria activates the cytoplasmatic proteases known as 
caspases. This process is regulated by Bax/Bcl-2 family proteins [93, 94]. In healthy cells, 
the major part of the pro-apoptotic Bax is located in the cytosol, although under apoptotic 
signaling this protein is transferred to outer mitochondrial membrane. An imbalance in this 
shift results in the consequent release of cytochrome c and other pro-apoptotic factors from 
mitochondria, the so-called mitochondrial outer permeabilization [95]. Oxidative damage 
to proteins may be caused by reactions of amino acid residues with ROS with the 
introduction of carbonyl groups in some residues, namely in lysine, arginine, proline, and 
threonine [66, 96, 97], and loss of thiol groups [66]. Carbonyl groups could be inserted into 
proteins by secondary reaction of the nucleophilic side chains of cysteine, histidine and 
lysine residues, with aldehydes produced during lipid peroxidation or with reactive 
carbonyl derivatives generated as a consequence of the reaction of reducing sugars, or their 
oxidation products with lysine residues of proteins. Hence, the presence of carbonyls is not 
necessarily indicative of oxidation of amino acid residues in proteins [97]. The insert of 
these groups may lead to inter- and intramolecular cross-links with protein amino groups 
and trigger loss of function. Therefore, accumulation of protein oxidation products in 
mitochondria may lead to loss of energy production and concomitant increased production 
of oxidants such as O2
•-
 and H2O2, potentiating mitochondrial dysfunction [65]. These 
modifications can also increase the susceptibility to proteolytic degradation since oxidized 
proteins are more easily targeted by the UPP, which is up-regulated by ROS [66, 98]. The 
detection of oxidatively modified proteins has been performed by immunoblotting using 
antibodies specific for these modifications, and subsequently identified by mass 
spectrometry [63, 97, 99]. Mitochondrial proteins from OXPHOS complexes I-V are 
particularly susceptibility to oxidation by carbonylation processes [100]. These 
carbonylated proteins were targeted by affinity chromatography-stable isotope labeling and 
were then identified by tandem mass spectrometry (MS/MS). Carbonylation of fatty acid 
binding proteins was also found, suggesting a possible decrease in fatty acid metabolism. 
Proteins involved in the citrate cycle also seem prone to carbonylation [101].  
 
 In addition to lipids and proteins, mtDNA is particularly susceptible to oxidation. 
Mitochondrial DNA is a double-stranded ring encoding 24 genes involved in local 
mitochondrial protein synthesis and 13 essential protein subunits of the OXPHOS 
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complexes I, III, IV and V [56, 102]. The close proximity to the electron transport chain, 
the lack of protective histones and the impaired DNA repair activity make mtDNA 
extremely susceptible to ROS [65, 66], which  damage leads to mitochondrial dysfunction 
with the consequent loss of cell energy [65, 103]. This damage can occur by an indirect 
mechanism or by direct interaction with hydroxyl radical (OH
•
). Indirect mechanism 
involves the peroxides through oxidation of SH groups of Ca
2+ 
channels
 
in the endoplasmic 
reticulum, which increases intracellular calcium and stimulates Ca
2+ 
- dependent 
endonucleases and ultimately leading to incorrect DNA fragmentations. OH
•
 causes 
modification of bases leading to DNA strand breakdown during replication and pairing 
errors [66]. The accumulation of mutations in the mtDNA can lead to alterations in cell-
signaling pathways, which in turn can induce cell dysfunction and apoptosis [66]. Several 
studies have suggested an association between mtDNA mutations and a decreased activity 
of complexes I and IV, particularly in long-lived postmitotic cells such as cardiomyocytes, 
skeletal muscle fibers, and neurons [65, 66, 104, 105]. Evidences shown decreased 
complexes I, III and IV activities associated with damage to mtDNA in mitochondria 
isolated from the gastrocnemius muscle of aging mice [106, 107]. Furthermore, alterations 
were not verified in complex II, which has no mtDNA coded component [106, 108]. 
However, in situ hybridization experiments indicate a strong association between mtDNA 
deletions and complexes II and IV abnormalities in old rhesus monkeys with senescent 
loss of skeletal muscle [109, 110]. These mtDNA deletions have been demonstrated to be 
tissue-specific, being more pronounced in the skeletal muscle and heart [111]. 
 
3.2. Mitochondrial phospholipid profile in wasted muscle 
 
The mitochondrial membrane phospholipids regulate mitochondrial activity of the ETC, 
mitochondrial protein import and ATP synthesis [81, 112], which are known to be 
impaired in wasted conditions [21, 71, 100].  Changes in mitochondrial lipid-lipid and 
lipid-protein interactions impacts integrity, fluidity and permeability of this organelle, 
leading to its dysfunction [81, 113, 114]. 
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Figure 5: Mitochondrial electron transport chain. Complex I (NADH dehydrogenase); complex II (succinate 
dehydrogenase); complex III (ubiquinone cytochrome c oxireductase); complex IV (cytochrome oxidase), 
complex V (ATP synthase) [adapted from 112, 115].  
 
Among phospholipids, phosphatidylcholine (PC), phosphatidylethanolamine (PE) 
and cardiolipin are the most abundant phospholipids in mitochondria [67]. Cardiolipin is a 
complex phospholipid that is specific of the inner mitochondrial membrane, and is not 
found in other subcellular membranes [80, 116]. PC, PE and CL are glycerophospholipids, 
also called phospholipids synthesized from the universal precursor phosphatidic acid (PA) 
[117, 118]. The glycerophospholipids have a role in cell structure and are involved in cell 
signaling and cell proliferation, thus they have been considered as potential biomarkers for 
several diseases[80]. Phospholipids usually consist of a glycerol backbone to which are 
attached two fatty acids (sn-1 and sn-2 acyl chains) and a phosphate group [117]. The 
phosphate group can bind to a polar molecule by phosphodiester bonds, forming the head 
group of phospholipid (Figure 6) [117]. The different combinations of length, degree of 
unsaturation of acyl chains and the constitution of the polar head group, makes 
phospholipids a  groupwhich is divided in several distinct classes depending on the group 
of the polar head. Each phospholipid class has different combinations of fatty acids 
attached to glycerol (Figure 6) [119, 120]. 
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Figure 6: General structure of glycerophospholipids (A) and of PC, PE and CL (B). R1, R2, R1’ and R2’ 
represent the fatty acyl chains esterified to glycerol backbone. PC – Phosphatidylcholine, PE – 
Phosphatylethanolamine, CL – Cardiolipin [adapted from 120]. 
 
 Mitochondria can synthesize several acidic phospholipids autonomously, 
including phosphatidic acid (PA), cytidine diphosphate-diacylglycerol (CDP-DAG), 
phosphatidylglycerol (PG), and cardiolipin. In contrast, phosphatidylcholine (PC), 
phosphatidylserine (PS), phosphatidylinositol (PI), and sterols are synthesized in other 
organelles and transported to mitochondria. CDP-DAG is an important PA derived since is 
utilized for the synthesis of PE and PC. Imported phosphatidylserine is rapidly 
decarboxylated within the mitochondrion to form PE [116].  
CL is a dimeric and negatively charged phospholipid that may be involved in 
protein import into mitochondria though interaction with positively charged signal 
sequences of precursor proteins [28]. This phospholipid has four acyl side chains attached 
to two glycerol molecules, in contrast to the typical lipids with two acyl chains and one 
glycerol backbone [80, 117]. Several studies have analyzed the fatty acids composition of 
CL in different tissues and 18:2 and 18:1 are the most abundant ones in rat heart, liver, 
kidney and skeletal muscle [121]. Moreover, it has been shown that the membranes 
containing CL with unsaturated fatty acyl chains, are linked to cytochrome c with higher 
binding affinity than those containing saturated CL [85]. CL is synthesized from PA via 
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several enzymatic steps common with other phospholipids [80, 117]. The biosynthesis of 
the phosphatidic acid occurs in the endoplasmatic reticulum and in the outer mitochondrial 
membrane [117]. The mitochondrial inner membrane contains all the enzymes of the CL 
pathway, namely those responsible for the formation of phosphatidic acid from acyl-CoA 
fatty acid and glycerol 3-phosphate, production of phosphatidyl-CMP, its transfer to 
another glycerol 3-phosphate and consequent hydrolysis of the latter yielding 
phosphatidylglycerol. The final reaction of this pathway whereby PG is combined with 
CDP-diacylglycerol to yield CL is catalysed by CL synthase (Figure 7) [117, 122].  
 
 
Figure 7: Pathway of cardiolipin (CL) biosynthesis [adapted from 117]. 
 
 PC, PE and CL have different saturated and unsaturated fatty acid, and therefore 
with different susceptibilities to oxidation, which increases exponentially as a function of 
the number of double bonds per fatty acid [123]. In fact, the major phospholipid 
components of the mitochondrial membranes are rich in unsaturated fatty acids and 
consequently are susceptible to oxygen radical attack because of the presence of double 
bounds, which can undergo peroxidation through a chain of oxidative reactions [124]. 
I. Introduction 
 ____________________________________________________________________________  
 
 
 
19 
 
Cardiolipin is particularly susceptible to oxidation by reactive oxygen species (ROS) due 
to the presence of the unsaturated fatty acyl chains linoleic acid or docosahexanoic acid, 
and also due to its close association with electron transport chain [80, 124]. In fact, the loss 
of CL has been attenuated by quenching or preventing the production of mitochondrial 
ROS in skeletal muscle [80], suggesting an association between the mitochondrial 
dysfunction and lipid peroxidation in skeletal muscle.  
 One of the most reactive ROS responsible for lipid peroxidation is OH
•
. Lipid 
peroxidation  by the OH
•
is initiated by the suptake  of one hydrogen atom from an allylic 
position, leading to the production of alkyl radicals (R
•
). This modification promotes the 
reorganization of the adjacent double bonds culminating in the production of other alkyl 
radicals, with formation of distinct intermediates with the radical species located in 
different positions of the fatty acyl chain. The alkyl radicals will react with oxygen  leading 
to the formation of peroxyl radicals (ROO
•
), which in turn produce one lipid 
hydroperoxide (ROOH) by acquiring one hydrogen atom. This lipid hydroperoxide can 
undergo other reactions leading to several oxidation products with different structures such 
as hydroxyl, hydroperoxi, epoxy and poly-hydroxy derivatives usually named long-chain 
oxidations products. Besides  the decomposition of the lipid hydroperoxides may lead to 
the formation of the alkoxyl radicals which may undergo posterior beta cleavage of the 
fatty acyl chain with formation of oxidation products with shortened fatty acyl chain that 
included dicarboxylic acids, aldehydes and hydroxyaldehydes, usually named short-chain 
products (Figure 8)  [125-128]. 
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Figure 8: Generation of the long chain and short chain oxidation products by radical oxidation [adapted 
from 128]. 
 
The peroxidation products are responsible for the loss of structural and functional 
characteristics of the membrane due to the increase the polarity of phospholipids and 
consequently decreasing the fluidity and increasing membrane permeability, or even cause 
disruption of the membrane integrity [81, 113, 129]. 
Mass Spectrometry (MS) has been used to identify and analyze phospholipids [79, 83, 
119]. Several studies have been performed in order to identify non-oxidized 
glycerophospholipids and the products derived from its oxidation [130, 131]. The products 
observed in MS/MS of oxidized phospholipids allows the identification of changes in fatty 
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acyl chain and specific characteristics such as presence of new functional groups in the 
molecule and its localization in the hydrocarbon chain [130]. The different oxidation 
products may be responsible for distinct biological effects thus increasing the relevance of 
identifying each specific oxidation product in order to understand their specific biological 
significance and effects [117].  
 Several studies concerning lipid alterations underlying pathological conditions 
were carried out by MS. Many researchers used lipidomic approaches for the study of 
phospholipids and their oxidation products in diverse injuries such as traumatic brain 
injury [83, 130]; in models of γ-radiation-induced [132, 133] or induced pro-apoptotic and 
pro-inflammatory stimuli [134]; in the study of cardiolipin loss and/or oxidation [80], 
among others. 
 Glycerophosphocholines (PC) are the most studied class of oxidized 
phospholipids by electrospray ionization mass spectrometry (ESI-MS) and oxidized 
products have been identified by MS in biological fluids and tissues [125, 128]. Saturated 
and unsaturated short-chain products containing terminal aldehyde and carboxylic groups 
were identified, some of which substituted with hydroxyl, keto and hydroperoxide groups, 
derived from the oxidation of diacylphosphatidylcholine in vitro, generated under Fenton 
reaction conditions (H2O2 and Fe
2+
) [125]. Reversed-phase liquid chromatography–mass 
spectrometry (LC-MS) also allowed the identification of these oxidation products [127].  
 Cardiolipin is a phospholipid that has been reported, in several studies, to be 
oxidized either in vitro and in vivo conditions [83, 86, 134]. Since CL is a mitochondria-
specific phospholipid and is critical for maintaining the integrity and function of membrane 
and osmotic stability, any disturbance of the CL profile leads to functional impairment. 
Indeed, loss of CL content, alterations of CL fatty acyl profile or increased CL 
peroxidation, have been correlated with mitochondrial dysfunction in several tissues in a 
variety of pathological conditions [80]. CL is associated with many mitochondrial proteins, 
namely the respiratory chain complexes I, III, IV, and V, the carrier family (ADP–ATP-
carrier, phosphate carrier, uncoupling protein), and peripheral membrane proteins such as 
cytochrome c and creatine kinase [80, 85, 135]. In fact, cytochrome c requires an 
electrostatic interaction to CL for successful electron transfer from reduced cytochrome c 
to molecular oxygen [80, 85, 123]. Therefore, the oxidized molecular species of CL 
derived from lipid peroxidation contributes to the permeabilization of the mitochondrial 
membrane, the release of cytochrome c and other pro-apoptotic factors into the cytosol [80, 
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136, 137] and compromises the activity of mitochondrial respiratory enzymes [80]. 
Moreover, CL levels have been found increased in the outer mitochondrial membrane 
during apoptosis [88]. Few data exist concerning evaluation of CL profiling in cancer 
cachexia (CC). Alterations in CL were found in brown adipose tissue from rats with CC 
[138]. A significant CL content increase (+55%) was also observed in liver mitochondria 
during CC [139].  
 Regarding CL oxidation, Bayir et al. [83] identified hydroxy and hydroxyl-
hydroperoxy derivatives using ESI-MS in mitochondria of rat brain after traumatic brain 
injury. Tyurina et al. [133] also verified hydroxy and hydroxyl-hydroperoxy derivatives by 
ESI-MS for CL in γ-radiation-induced lung injury. An in vitro study  performed with 
MALDI-TOF-MS and thin-layer chromatography identified phosphatidic acid and 
dyacilphosphatidyl-hydroxyacetone as oxidation products of CL induced by lipossomes γ-
radiation and were generated from cleavage on central glycerol molecule [132].  
Maciel et al. [140] identified new short chain products resulted from β-cleavage of alkoxyl 
radicals at C9 and C13 of cardiolipin oxidation, in nephrotoxic disturbances induced by an 
aminoglycoside antibiotic associated with mitochondrial dysfunction and lipid 
peroxidation in rat kidney tissue. Tyurin et al. [134] identified CL hydroperoxides 
accumulated in apoptotic cells and mouse lung of C57BL/6 mice after pro-apoptotic and 
pro-inflammatory stimuli, similarly to that observed for PS. 
 Oxidation of CL have been correlated with Cyt c release to the cytosol and the 
externalization of PS in apoptotic cells. In fact, the interaction of cytochrome c with 
oxidized phosphatidylserine (PS) has also been related with its migration across the cell 
membrane. Similarly to CL/cyt c interactions in mitochondria, the formation of PS/cyt c 
complexes in the cytosol leads to oxidized PS, which seems  to be essential for the 
transduction of apoptotic signals [85]. Bayir et al. [83] also proposed the presence 
signaling role of PS hydroperoxides derivatives in traumatic brain injury. PS 
hydroperoxides were also identified by ESI-MS in cells and tissues under 
inflammatory/oxidative stress conditions [134]. An oxidative lipidomic analysis of γ-
radiation-induced lung injury allowed to verify an non-random oxidation of phospholipids, 
with identification of hydroxy and hydroxyl-hydroperoxy derivatives by of PS while more 
abundant PLs, such as PC and PE, remained non-oxidized [133].  
 Concerning the phosphatidylethanolamine oxidative products, few studies are 
known. A study relying on three different oxidation systems and using multiple reaction 
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monitoring identified short-chain products with terminal aldehyde and carboxylic derived 
from phosphatidylethanolamines derivatives. The systems used were autoxidation in 
presence of Cu (II), UV radiation and myeloperoxidase (MPO) [136].   
   
4. Aims of this thesis 
 
In order to better elucidate the molecular mechanisms underlying cancer-related 
skeletal muscle wasting, the aims of the present study were to: 
 
 i) Evaluate how bladder cancer-induced cachexia affects mitochondrial OXPHOS 
activity and susceptibility to oxidative damage and/or apoptosis; 
 ii) Characterize the impact of bladder-cancer related cachexia on mitochondrial 
lipid profile of gastrocnemius muscle;  
iii) Evaluate how mitochondrial lipidome profile relates to alterations in 
mitochondrial OXPHOS functionality and proteins suggestive to susceptibility to 
apoptosis; 
Data integration will allow a better understanding of bladder cancer-induced muscle 
wasting pathogenesis and will ideally give clues for the development of strategies to 
counteract muscle wasting in oncologic patients. 
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II. Material and Methods 
1. Experimental Design 
 
In order to achieve the proposed aims for this study, the experimental approach 
shown in Figure 9 was performed. Briefly, 23 Wistar rats, randomly divided in two 
groups: animals with bladder cancer induced by the exposition to N-butyl-N-(4-
hydroxybutyl)-nitrosamine in the drinking water for 20 weeks (BBN, n=13) and healthy 
animals (CONT, n=10). After 28 weeks of the beginning of the protocol, all animals were 
sacrificed and gastrocnemius dissected out for mitochondria isolation with recourse to 
sequential steps of enzymatic digestion, mechanical disruption and differential 
centrifugation. The mitochondrial fractions were used for OXPHOS activity assessment, 
lipidomic characterization and the analysis of protein targets using western blotting. The 
experimental groups and methodological approaches used are described in the following 
sections. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Scheme of the methodological procedures used in the analysis of different biochemical parameters 
in gastrocnemius muscle of rats with bladder cancer-related cachexia and controls. 
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 Determination of Carbonylated Mitochondrial Proteins by Western blotting; 
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2. Chemicals 
 
N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN) was purchased from Tokyo Kasey 
Kogyo (Japan). All other reagents and chemicals used were of highest grade of purity 
commercially available. Rabbit polyclonal anti-ETFDH antibody (cat. no. Abcam 
ab91508), rabbit polyclonal anti-ETFβ antibody (cat. no. ab73986), mouse monoclonal 
anti-ATPβ antibody (cat. no. ab14730), rabbit polyclonal anti-UCP-3 antibody (cat. no. 
ab3477) were acquired from Abcam (Cambridge, UK).  Mouse monoclonal anti-
cytochrome c antibody (cat. no. BD556433) was obtained from BD Biosciences 
(Pahrmingen). Mouse monoclonal anti-Bcl-2 antibody (cat. no. sc-7382) and rabbit 
polyclonal anti-Bax antibody (cat. no. sc-493) were acquired from Santa Cruz 
Biotechnology, INC. (CA, USA). Rabbit polyclonal anti-DNP antibody was obtained 
from DakoCytomation (Hamburg; Germany). Secondary peroxidase-conjugated 
antibodies (anti-mouse IgG and anti-rabbit IgG) were obtained from GE Healthcare 
(Buckinghamshire, UK). The lysophosphatdylcholine (LPC), phosphatidic acid (PA),  
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycrol (PG), 
phosphatidylinositol (PI),  phosphatidylserine (PS), sphingomyelin (SM), and cardiolipin 
(CL) standards were purchased from Sigma-Aldrich (Madrid, Spain), triethylamine 
(AcrosOrganics), chloroform (HPLC grades), methanol (HPLC grades), ethanol 
(Panreac), primuline (Sigma), purified milli-Q water (Millipore, USA). All the reagents 
were used without further purification. TLC silica gel 60 plates with concentration zone 
(2.5x20cm) were purchased from Merck (Darmstadt, Germany). 
3. Animal Protocol 
 
The animal protocol was accomplished using twenty three female Wistar rats. The 
animals were obtained at the age of 5 weeks from Harlan (Barcelona, Spain). The rats 
were used in this study after a week of acclimatization. During the experimental protocol, 
animals were housed in groups of 4 rats/cage, in a controlled environment at a room 
temperature of 22±3ºC and 60±10% of relative humidity with 12:12h light-dark cycle, 
with free access to food and water.  The animals were randomly divided into two groups: 
control group (CONT; n=10 rats) and urothelial carcinogenesis group (BBN; n=13 
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rats). The following protocol was approved by the Portuguese Ethics Committee for 
Animal Experimentation. 
In order to induce urothelial carcinogenesis, one group of animals was treated 
with N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN group), which was administered in 
the drinking water, in light impermeable bottles, at a concentration of 0.05%. No 
chemical supplementation was added to the drinking water of control animals. The 
urothelial carcinogenesis group was exposed to BBN for 20 weeks and was maintained 
with normal tap water until the end of the experiment. After 28 weeks of the beginning of 
the protocol, all animals were sacrificed with 0.4 % sodium pentobarbital (1 mL/Kg, 
intraperitoneal), blood was collected from heart. The urinary bladders were inflated in 
situ by injection of 10% phosphate-buffered formalin (300 mL), ligated around the neck 
to maintain proper distension and then were immersed in the same solution for 12 h. 
After fixation, the formalin was removed; the urinary bladder was weighed and cut into 
four strips and was routinely processed for haematoxylin and eosin staining.   
4. Mitochondria Isolation from Gastrocnemius Muscle  
 
The gastrocnemius muscles were extracted during animals’ sacrifice for the 
preparation of isolated mitochondria, as previously described [141] with some alterations. 
All the procedures were performed on ice or below 4ºC.   Briefly, muscles were washed 
three times with 20mM MOPS, 110 mM KCl, 1 mM EGTA, pH 7.5. The blood-free tissue 
was minced with scissors and then incubated in the before mentioned buffer with 0.25 
mg/mL trypsin (Promega, Wisconsin, USA). After 25 min on ice, albumin fat-free (Sigma, 
St. Louis, MO, USA) was added to a final concentration of 10 mg/mL. The tissue was 
subsequently rinsed three times with buffer and then homogenized with a Potter 
homogenizer (Teflon pestle). The homogenate was centrifuged at 14.500 g for 10 min. The 
resulting pellet was re-suspendend with 20 mM MOPS, 110 mM KCl, 1 mM EGTA, pH 
7.5. The resulting suspension was centrifuged at 750 g for 10 min, and the resulting 
supernatant was centrifuged at 12.500 g for 10 min. The mitochondrial pellet was re-
suspending in a small volume of buffer (250mM sucrose, 10 mM Tris–HCl, 0.1 mM 
EGTA, pH 7.4), and it was stored at -80 ºC for further use.  
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5. Determination of Total Protein Concentration by DC assay  
 
The amount of total protein was determined in mitochondrial fractions by the DC 
protein assay (Bio-Rad, Hercules, CA, USA), based in Lowry et al. [142]. Briefly, 20 μl of 
S reagent from the Bio-Rad kit was added to 1 ml of A reagent (to make A´ reagent). Then, 
50 μl of A´reagent and 400 μl of B reagent was added to 5 μl of sample and incubated at 
room temperature for 15 min. Standard solutions of bovine serum albumin (BSA) between 
0.16 to 10 mg/ml were prepared and treated in parallel with the samples. At last, the 
absorbance of all the samples was measured at 750 nm in a microplate reader (Multiscan 
90, ThermoScientific). 
6. Determination of Respiratory Chain Complexes II and V Activities 
 
The respiratory chain complexes II and V activities were determined 
spectrophotometrically after disruption of mitochondrial fractions by a combination of 
freeze-thawing cycles in hypotonic media (25 mM potassium phosphate, pH 7.2). 
Complex II activity was determined according to Birch-Machin et al. [143]. Briefly, 
mitochondria were pre-incubated with 25mM potassium phosphate buffer, pH 7.2, 5mM 
MgCl2 and succinate at 30ºC for 10 min. Antimycin A (2 μg/mL), rotenone (2 μg/mL), 
2mM KCN and 50 μM of DCIP were added and the absorbance variation was measured 
at 600 nm for 3 min. Then, 65μM of ubiquinone was added and a new determination at 
600 nm for 3 min was performed. ATP synthase activity was measured according to 
Simon et al. [144]. The phosphate produced by hydrolysis of ATP reacts with ammonium 
molybdate in the presence of reducing agents to form a blue-color complex, the intensity 
of which is proportional to the concentration of phosphate in solution. This reaction was 
carried out by incubation with a test solution (3.3g of ammonium molibdate, ferrous 
sulfate (4 g/500 mL), 0.37M of sulfuric acid) for 15 min, followed by measure of 
absorbance at 610 nm. Oligomycin was used as an inhibitor of mitochondrial ATPase 
activity. Standards of inorganic phosphate were performed to measure the released 
phosphate in the ATP hydrolysis. The absorbance was determined using a microplate 
reader (Multiscan 90, ThermoScientific). 
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7. Analysis of Protein Expression by Western blotting 
 
In order to evaluate the expression of mitochondrial proteins, these was separated 
according to their molecular weight on polyacrylamide gels in denaturing and reducing 
conditions, by applying an electric current of 200 V. A given sample sample corresponding 
to 20 μg of protein was loaded on a 12.5% or 15% SDS-PAGE, prepared according to 
Laemmli [145].  After separation, proteins were transferred to a nitrocellulose membrane 
(Millipore
® 0.45 μm of porosity) by electroblotting at 200 mA for 2 h in transfer buffer (25 
mM Tris, 192 mM glycine, 20% methanol). To avoid non-specific binding the 
nitrocellulose membrane was blocked in a solution of 5% (w/v) nonfat dry milk in TBS-T 
(100 mM Tris pH 8.0, 150 mM NaCl and 0.05% Tween 20) for 1 h at room temperature. 
The membrane was then incubated with primary antibody diluted 1:1000  in blocking 
solution (anti-ETFDH, anti-ETFβ, anti-ATPβ, anti-UCP3, anti-Bcl-2, anti-Bax or anti-
cytochrome c) for 2 h at room temperature or overnight at 4ºC. After three washes with 
TBS-T the membrane was incubated with secondary antibody horseradish peroxidase-
conjugated anti-rabbit or anti-mouse for 1 h at room temperature. The membrane was 
washed three new times with TBS-T and the blots were developed using 
chemiluminescence ECL reagents (Amersham Pharmacia Biotech
®
) according to the 
manufacturer’s instructions, followed by exposure to X-ray films (Kodak Biomax Light 
Film, Sigma
®
). Films were scanned using a Gel Doc XR + System (Bio-Rad
®
) and bands 
intensity quantified with the QuantityOne
 
imaging software (version 4.6.3, Bio-Rad
®
). 
8. Determination of Carbonylated Mitochondrial Proteins by Western Blotting 
 
Carbonylated proteins were assayed according to Robinson et al. [99]. Briefly, a 
given volume (V) of sample containing 20 μg of protein was derivatized with 2,4-
dinitrophenylhydrazine (DNPH). The sample was mixed with 1 V of 12 % SDS plus 2 V 
of 20 mM DNPH/10% TFA, followed by 30 minutes incubation in dark. After the 
incubation period 1.5 V of 2 M Tris-base/18.3% of β-mercaptoethanol was added for 
neutralization. The derivatized proteins were applied in a 12.5 % SDS-PAGE, prepared 
according to Laemmli [145]. After separation by molecular weight, proteins were 
transferred for a nitrocellulose membrane blots, blocked with 5% (w/v) nonfat dry milk in 
TBS-T for 1 h and then incubated for 2 h at room temperature with rabbit anti-DNP 
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antibody diluted 1:5000 in blocking solution. After three washes with TBS-T the 
membrane was incubated for 2 h at room temperature with secondary antibody horseradish 
peroxidase-conjugated anti-rabbit diluted 1:1000 in blocking solution. The membrane was 
washed three new times with TBS-T and detection was carried out with 
chemiluminescence ECL reagents (Amersham Pharmacia Biotech
®
) according to the 
manufacturer’s instructions. Then, the membrane was exposed to X-ray films (Kodak 
Biomax Light Film, Sigma
®
). Films were scanned using a Gel Doc XR + System (Bio-
Rad
®
) and bands intensity quantified by QuantityOne
 
imaging software (version 4.6.3, Bio-
Rad
®
). 
 
9. Determination of Mitochondria Lipid Peroxidation levels 
 
Lipid peroxidation was assayed spectrophotometrically in mitochondrial fractions 
according to Bertholf et al. [146] by measuring the formation of thiobarbituric acid 
reactive substances (TBARS). So, to sample aliquots of 75 μL was added 150 μL of TCA 
10% followed by vortex and centrifugation for 5 min at 15000 rpm. To 125 μL of the 
resulting supernatant, 125 μL of TBA 1% was added. The color reaction was developed 
by incubating the mixtures at 100 ºC for 10 min. Finally, TBARS levels were measured at 
540 nm using a microplate reader (Multiscan 90, ThermoScientific). 
10. Phospholipids Extraction 
 
Total lipid content, including phospholipids were extracted from the mitochondrial 
fractions using the Bligh and Dyer method [147]. Briefly, 3.75 mL of chloroform:methanol 
1:2 (v/v) was added to 1mL of gastrocnemius mitochondrial fraction (corresponding 
approximately to 8 mg of protein), well -vortexed and incubated on ice for 30 min. Then, 
1.25 mL of chloroform and 1.25 mL of mili-Q H2O were added. After vortexed well, the 
mixture was centrifuged at 1000 rpm for 5 min at room temperature to obtain a two-phase 
system: the aqueous phase on top and the organic phase below from which lipids were 
obtained. At last, the extracts were dried in a nitrogen flow, re-suspended in 300 μL of 
chloroform and stored at -20 ºC for subsequent analysis. 
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11. Quantification of Phospholipids by Phosphorous Assay 
 
The total content in phospholipids of the total lipid extract, as well as the amounts of 
each phospholipid class present in each spot separated by TLC, were determined by a 
phosphorous quantification method according to Bartlett and Lewis [148]. To quantify the 
total PL extract, 10 μL of the total lipid extract were transferred to a glass tube and dried 
under a nitrogen flow. To quantify the different classes separated by TLC, the spots were 
scraped off from the plates directly to glass tubes for quantification. Then, 650 μL of 
perchloric acid (70%, w/v) was added to the samples, which were then incubated at 180 ºC 
for 1h in a heating block (Stuart, U.K.). To all tubes were added 3.3 mL of mili-Q H2O, 0.5 
mL of ammonium molibdate (2.5g ammonium molibdate/100 mL of H2O) and 0.5 mL of 
ascorbic acid (10g ascorbic acid/100 mL of H2O) and vortexed well after the addition of 
each solution, followed by incubation in a water bath at 100 ºC for 5 min. Standards from 
0.1 to 2 μg of phosphate underwent the same sample treatment. Samples from TLC were 
centrifuged at 4000 rpm for 5 min to separate PLs from silica. Finally, the absorbance of 
standards and samples was measured at 800 nm, in a microplate reader (Multiscan 90, 
ThermoScientific). The relative content of each PL class was calculated by relating the 
amount of PL in each spot to the total amount of PLs in the sample. 
 
12. Separation of Phospholipids Classes by Thin-Layer Chromatography (TLC) 
 
Phospholipids classes from the total lipid extract were separated by thin-layer 
chromatography (TLC) using plates of silica gel 60 with concentration zone 2.5 x 20 cm. 
Prior to separation the silica plates were washed with a solution of chloroform: methanol 
(1:1 v/v) and dried in the hotte for 15 min. Then, plates were sprayed with a solution of 
boric acid in ethanol (2.3% w/v) and dried in an oven at 100 ºC for 15 min. Then, twenty 
μL of sample of total lipid extract was applied in the TLC. The spots on TLC were dried in 
nitrogen flow and developed in solvent mixture with 
chloroform/ethanol/water/triethylamine (30:35:7:35, v/v/v/v). After complete elution, and 
after eluent evaporation, the TLC plates were sprinkle with a primuline solution (50 μg/100 
mL acetone:water, 80:20, v/v), and visualized with a UV lamp (λ=254 nm). Identification 
of the different classes of PLs was carried out by comparison with phospholipids standards. 
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For further analysis, the spots were scraped off from the plates, and the phospholipids 
present in each spot were quantified using the phosphorous assay. The percentage of each 
PL class was calculated, relating the amount of phosphorus in each spot to the total amount 
of phosphorus in the sample, thus giving the relative abundance of each PL class. 
 
13. Fatty Acid Quantification by Gas Chromatography with Flame Ionization 
Detector (GC-FID) 
 
In order to identify and quantify the fatty acids present in total lipid extracts, GC-FID 
was performed, according to Pimentel et al. [149]. For that, fatty acid methyl esters were 
formed by addition of KOH in methanol solution. Then, twenty µL of total lipid extract 
was transferred to centrifuge tubes and dried in nitrogen current. Then, 1 mL of methyl 
heptadecanoate (C17:0) internal standard solution (0.75g/L in n-hexane with 1:100 
dilution) was added. Plus, 200 μL of KOH (2M) in methanol was added, the mixture was 
vortexed well (1-2 min) and was then centrifuged at 2000 rpm for 5 minutes. The upper 
phase was collected to eppendorf and the solvent was dried in a nitrogen flow. Finally, the 
sample was ressuspended in 20 μL of n-hexane, and 4 μL of this solution was injected to 
GC. Fatty acids were identified by the retention times previously determined by the same 
procedure with a mixture of standard fatty acids. Peak areas corresponding to each fatty 
acid were calculated for a relative quantification of fatty acids.  
 
13.1. GC-FID Conditions 
 
The GC injection port was programmed at 250 ºC and the detector at 270ºC. Oven 
temperature was programmed in three ramps, 50ºC for 3 min, 25ºC/min until 180ºC for 6 
min and 40ºC/min until 260ºC for 3 min, respectively. The carrier gas was hydrogen 
flowing at 1.7 mL/min. The column used was DB1 with 30 m, internal diameter 
of 0.250 mm and 0.10 μm film thickness. Data acquisition and analysis was carried out 
with TotalChrom Navigator Software. 
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14. 4  Identification of Phospholipid Molecular Species by High-Performance Liquid 
Chromatography – Mass Spectrometry (HPLC-MS)  
 
The identification of PL molecular species and evaluation of changes in cancer-
related cachexia phospholipid classes were carried out by LC-MS using a HPLC system 
(Waters Alliance 2690) coupled to an electrospray (ESI) linear ion trap mass spectrometer 
(ThermoFinnigan, San Jose, CA, USA). The mobile phase A is composed of 10% water 
and 55% acetonitrile with 35% (v/v) of methanol. The mobile phase B is composed of 
acetonitrile 60%, methanol 40% with 10mM ammonium acetate. For injection, 15 μL of 
total lipid extract were diluted in the mobile phase A and reaction mixture was introduced 
into Ascentis Si HPLC Pore column (15 cm x 1.0 mm, 3 μm) (Sigma-Aldrich). The solvent 
gradient started with 0% of A and linear increased to 100% of A during 20 min, and 
maintain in these conditions for 35 min, returning, to the initial conditions in min. The flow 
rate in the column was 16 μL/min obtained using a pre-column split (Acurate, LC 
Packings, USA). LC-MS was performed with an internal standard [150]. 
 
14.1. Electrospray Mass Spectrometry Conditions  
 
 LC-MS and ESI-MS were acquired in an electrospray linear ion trap mass 
spectrometer (ThermoFinnigan, San Jose, CA, USA). MS data was obtained using the 
following electrospray conditions: electrospray voltage was 4.7 kV in negative mode and 5 
kV in positive mode; capillary temperature was 275 ºC and the sheath gas flow of 25 U. 
An isolation width of 0.5 Da was used with a 30-ms activation time for MS/MS 
experiments. Full scan MS spectrum and MS/MS spectrum were acquired with a 50-ms 
and 200-ms maximum ionization time, respectively. Normalized collision energy
TM
 (CE) 
varied between 17 and 20 (arbitrary units) for MS/MS. Data acquisition and analysis was 
carried out with a Mass Lynx data system V4.0 (Waters, Manchester, UK) and a Xcalibur 
data system (V2.0), respectively. 
15. Statistical Analysis 
 
 Data is presented as mean ± standard deviation (of raw data or expressed as 
percentage of control). The Kolmogorov -Smirnov test was used to test normality of 
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distribution for all data. Significant differences among groups were evaluated with the 
unpaired student’s t test, using GraphPad Prism® software (version 5.00). The level of 
significance was set at p < 0.05. 
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III. Results 
 
1.  Characterization of animal’s response to BBN administration 
 
After 20 weeks of oral exposition BBN (N-butyl-N-(4-hydroxybutyl)-nitrosamine)  
followed by 8 weeks of tap water, rats evidenced a significant 17% loss of body weight 
(p<0.001), which seems related to signs of nodular hyperplasia in the bladder, and simple 
hyperplasia and dysplasia (in more than 75% of the animals). No histopathological changes 
in the urothelium were observed in control rats. No changes in food consumption were 
noticed. The 17% loss of body weight observed in BBN rats might be viewed as moderate 
cachexia according to the cachexia score for humans (CASCO) [4]. BBN-related body 
weight decrease was accompanied by a 12% reduction in gastrocnemius muscle mass 
(p<0.05 vs. CONT) (Table 1). No significant differences of muscle-to-body weight ratio 
were observed between groups (data not shown). 
 
Table 1: Characterization of the animals used in the study. 
Experimental group 
Body weight  
(g) 
Muscle mass  
(g) 
 
CONT 309.0 ± 21.1 3.3 ± 0.3  
BBN 256.6 ± 4.1
***
 2.9 ± 0.1
*
  
Data are expressed as mean ± standard deviation. (*p<0.05 vs CONT; *** p< 0.001vs CONT) 
2. Effect of Bladder Cancer-related Cachexia on Mitochondrial Metabolic 
Activity  
 
 
In order to evaluate the effect of cancer-related cachexia on bladder mitochondrial 
functionality, the activity of the respiratory chain complexes II and V was 
spectrophotometrically measured in the mitochondrial fractions of gastrocnemius muscle 
(Table 2) and a decreased activity of both complexes was observed (p<0.001 vs CONT).  
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Table 2: Effect of cancer-related cachexia on OXPHOS complexes II and V activities in CONT 
and BBN rats. 
Experimental group 
 
Succinate:ubiquinone reductase 
(μmol/min/g) 
 
ATP synthase 
(μmol/Pi/min/mg) 
 
CONT 4.805 ± 0.3599 11.18 ± 0.9436  
BBN 2.908 ± 0.2426
***
 6.980 ± 0.6050
***
  
Data are expressed as mean ± standard deviation. (*** p< 0.001vs CONT)  
 
The 40% decrease of succinate:ubiquinone reductase activity and 38% diminishing 
of ATP synthase activity, was accompanied by a significant decrease of ATP synthase 
subunit beta expression (Figure 10B). The same tendency was noticed for the electron 
transporter cytochrome c (Figure 10A).   
 
Figure 10: Cytochrome c (A) and ATP synthase β (B) expression evaluated by western blotting in 
gastrocnemius muscle from BBN and control animals. Representative western blots are present above the 
corresponding graph. Values are expressed as mean ± standard deviation. (*p<0.05 vs CONT). 
 
The expression of ETFβ and ETFDH was also analyzed and decreased levels of 
both proteins were verified in mitochondria of BBN rats (Figure 11). The decreased 
content of these proteins corroborate the lower OXPHOS activity observed since energy 
production depends on ETF/ETFDH activity and ETFDH is also responsible for 
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ubiquinone reduction in the mitochondrial membrane [151]. Concomitantly, 
mitochondrial levels of the uncoupling protein UCP-3 were increased due to BBN 
exposition (p<0.001; Figure 11C), and its uncoupling action results in OXPHOS 
inefficiency [72, 74].  
 
 
 
Figure 11: Effect of BBN on ETFβ (A), ETFDH (B) and UCP3 (C) expression evaluated by western 
blotting. Representative immunoblots are presented above the corresponding graph. Values are expressed 
as mean ± standard deviation. (*p<0.05 vs CONT; ***p<0.001 vs CONT) 
 
 
3. Effect of Bladder Cancer-related Cachexia on Mitochondria Susceptibility to 
Oxidative Damage and/or Apoptosis 
 
To evaluate the effect of bladder cancer-related cachexia on mitochondrial proteins 
susceptibility to oxidative damage, the total content of carbonylated proteins was measured 
by western blotting after derivatization with dinitrophenylhydrazine (Figure 12). The 
results obtained show an increase of carbonylation levels in BBN mitochondria (***p< 
0.001 vs CONT). No distinct band patterns of carbonylated proteins were observed 
between groups, being proteins with MW in the range of approximately 10-60 kDa 
particularly susceptible to oxidative damage (Figure 12).  
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Figure 12:  Effect of BBN on carbonyl content and profile in mitochondria (A). Representative image of 
western blotting data is presented (B). Values are expressed as mean ± standard deviation. (***p< 0.001vs 
CONT) 
 
The expression of apoptosis-regulating proteins Bax and Bcl-2 was also analyzed to 
evaluate the susceptibility of mitochondria to apoptosis on cancer-related cachexia (Figure 
13). Bax/Bcl-2 ratio was higher in BBN mitochondria suggesting a higher susceptibility of 
wasted muscle to apoptosis (Figure 13C). 
   
 
 
Figure 13: Effect of BBN in Bax (A), Bcl-2 (B) and Bax/Bcl-2 ratio (C) expression evaluated by western 
blotting in mitochondria of gastrocnemius muscle from CONT and BBN groups. Representative western 
blots are present above the corresponding graph. Values are expressed as mean ± standard deviation. 
(*p<0.05 vs CONT ;*** p< 0.001vs CONT) 
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4. Effect of Bladder Cancer-related Cachexia on Mitochondria Susceptibility to 
Lipid Peroxidation 
 
To evaluate the susceptibility of BBN administration on mitochondrial lipids to 
peroxidation, TBARS were evaluated in isolated mitochondria and no significant 
differences were observed in the mitochondria from BBN-treated animals (Figure 14), in 
opposite to the verified for mitochondrial proteins.  
 
 
Figure 14:Effect of BBN on gastrocnemius mitochondria thiobarbituric acid reactive substances 
(TBARS).Values are presents as mean ± standard deviation of 5 replicates (*p<0.05 vs. CONT). 
 
 
5. Effect of Bladder Cancer-related Cachexia on Phospholipid Profile of 
Mitochondria  
 
In order to evaluate possible changes in mitochondria phospholipid profile between 
controls and cachexia, PL profileof total lipid extracts of  mitochondria isolated from 
gastrocnemius muscle was evaluted using a lipidomic approach. The results obtained will 
be presented in the following sections. 
 
5.1. Evaluation of Phospholipids Profile in Mitochondria  
 
 To evaluate the effect of bladder cancer-related cachexia in mitochondria PL 
profile, the total lipid extract was fractionated by thin-layer chromatography (TLC) 
(Figure 15). The identification of PL classes was accomplished by comparison with PL 
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standards applied in the same TLC plate. This approach allowed the separation and 
identification of mitochondrial phospholipids (PL) classes from gastrocnemius muscle 
tissue: phosphatidylcholines (PC), phosphatidylethanolamines (PE), cardiolipin (CL), 
phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylglycerol (PG), 
phosphatidylinositol (PI) and sphingomyelin (SM). 
 
 
Figure 15: Separation of phospholipid classes by thin-layer chromatography from the total lipid extracts 
obtained from mitochondria of rats control (CONT) and with bladder cancer-related cachexia (BBN). PI – 
phosphatidylinositol; PA - phosphatidic acid; SM – sphingomyelin;  PS - phosphatidylserine; PG – 
phosphatidylglycerol; CL – cardiolipin; PC - phosphatidylcholine; PE – phosphatidylethanolamine. 
  
  After the separation by TLC, the relative PL content (%) present in each spot was 
evaluated by phosphorous assay (Figure 16) as described by Bartlett and Lewis [148]. 
This analysis was carried out in triplicate for each experimental group.  
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Figure 16: Relative content of phospholipid (PL) classes in the total lipid extracts obtained from 
mitochondria of skeletal muscle of rats, controls (CONT) and bladder cancer-related cachexia (BBN) 
conditions. The PL classes were separated by thin-layer chromatography and the phosphorous content of 
each spot was determinate by relating to the amount of phosphorous total lipid extract. SM – 
sphingomyelin;  PC - phosphatidylcholine; PI – phosphatidylinositol; PS - phosphatidylserine; PG – 
phosphatidylglycerol; PE – phosphatidylethanolamine; PA - phosphatidic acid; CL – Cardiolipin. Values 
are expressed as mean ± standard deviation from triplicate experiments is shown. (**p<0.01 vs CONT; 
***p<0.001 vs CONT). 
 
The most abundant PL class in all mitochondrial samples was phosphatidylcholine 
(CONT=37%; BBN=51%) and phosphatidyethanolamine (CONT=26%; BBN=26%), 
followed by cardiolipin (CONT=14%; BBN=9%). These results are in accordance with the 
literature that reported these three PL classes as the most abundant in mitochondria [67].  
The oral administration of N-butyl-N-(4-hydroxybutyl)-nitrosamine for 20 weeks led to 
alterations in mitochondrial phospholipid profile detected by changes in phospholipids 
relative content (Figure 16). In the control group, the relative abundance of classes 
followed the order PC>PE>CL>PA>PG>PI>PS>SM and in cancer-related cachexia group 
this order was changed for PC>PE>CL>PA>PS>SM>PI>PG . From the analysis of Figure 
16 we can depict the significantly decreased in the relative content of PG, PA and CL in 
BBN mitochondria (p<0.001 for PG; p<0.01 for CL and PA) while PC were significantly 
increased in the case of mitochondria of rats treated with BBN ,(p<0.001). No significant 
variation was observed for PE content. SM and PS showed a tendency to increase in rat 
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mitochondria from bladder cancer-related cachexia although not in a statistically 
significant way. PI class showed a tendency to decrease. 
   
 To integrate the alterations verified in PL classes in mitochondria from animals 
with cancer-related cachexia, data was clustered in metabolic pathways using the Metscape 
plugin from Cytoskape platform [152]. The general overview of phospholipids 
biosynthesis allows comprehending the effect of urothelial carcinoma on the remodeling of 
PL classes (Figure 17). The glycerophospholipid (PG) and phosphatidylinositol phosphate 
metabolic pathways are down-regulated in cachectic mitochondria (Figure 18). This is in 
accordance with data obtained from TLC that showed that PG content was decreased in 
cachexia group (p<0.01; Figure 16). Since PG is a precursor of CL (Figure 17) this is a 
statistically significant decrease in the levels of CL, with cachexia (KEGG reaction 
RE1197, Figure 18)  
 
 
 
Figure 17: Main phospholipids biosynthetic pathways. Broken arrows indicate more than one step. DAGK – 
diacylglycerol kinase, CDP-DAG – cytidine diphosphate diacylglycerol,  PLC – phospholipase C , LPPs – 
phosphate phosphohydrolases, PLD – phospholipase D, PLA2- phospholipase A2, LPCAT1-
lysophosphatidylcholine acyltransferase 1.  
 
 
 Concerning phosphatidylinositol phosphate metabolism, the decrease in PI content 
although not statistically significant may be due to the increase of phospholipases action 
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(KEGG reaction REF3273, Figure 18). Decrease of PI class can be also due to 
phosphorylation, with formation of phosphoinositides phosphorylated (PIPs) (Figure 17), 
which play a main role in apoptotic cellular events [153]. Phosphatidic acid constitutes the 
molecular basis for the formation of all other phospholipids and showed decreased levels 
in BBN group. In overall, phospholipids synthesized autonomously by mitochondria, 
namely PA, PG and CL showed a decreased relative content which seems related with 
mitochondrial dysfunction observed. 
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Figure 18: Phospholipid metabolic pathways. PL classes found up- and down-regulated (highlighted in green and red, respectively) in mitochondria from animals with cancer-related 
cachexia and the reactions and enzymes involved. Metscape plugin from Cytoskape platform was used in data clustering. 
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5.2.Evaluation of Fatty Acids Profile in Mitochondria by GC-FID 
 
In order to evaluate if the fatty acid profiling in total lipid extracts change  in BBN 
treated rats , analysis of the fatty acids was performed by GC-FID (Figure 19). The results 
obtained showed a statically increases in the C18:2 and a decrease C18:0 content. Also a 
tendency of a decrease in the saturated fatty acids relative content (C18:0 and C16:0) 
accompanied by an increase in the polyunsaturated fatty acids levels (C18:2 and C22:6) is 
observed Alterations in phospholipid fatty acyl composition impacts mitochondria 
membrane fluidity and permeability, and consequently  its integrity [79]. Though no 
statistically significant, is interesting to highlight the increase of docosahexanoic acid 
content (C22:6), since it has been related to an increase of mitochondrial membrane 
permeability [155]. 
 
 
 
Figure 19: Quantification of fatty acid content of mitochondrial total lipid extracts by GC-FID. Values are 
expressed as mean ± standard deviation from triplicate experiments is shown. (*p<0.05 vs CONT). 
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5.3. Evaluation of Phospholipid Classes Profile in Mitochondria by HPLC-MS 
 
To assess the effects of bladder cancer-related muscle wasting on molecular profile 
within each PL class, lipid extracts from isolated mitochondria of the gastrocnemius 
muscle were analyzed by HPLC-MS. With this approach a separation of phospholipid 
classes and sequential analysis of molecular species by MS and MS/MS of each class was 
achieved. This analysis was further complemented with the assessment by tandem mass 
spectrometry (MS/MS) to identify the fatty acyl composition in each PL molecular 
species. The identification of PC, SM and LPC classes was performed with ESI-MS in 
positive mode, with formation of [MH]
+
 ions. Molecular species of PE, PA, PS, PI, PG 
and CL were analyzed by ESI-MS in negative mode, that allow the identification of the 
[M-H]
-
 ions and also of the [M-2H]
2-
 for CL. An example of LC-chromatogram showing 
the elution of each phospholipid class is shown in Figure 20. 
 
 
 
 
 
 
 
 
 
 
Figure 20: Example of total ion chromatograms from the HPLC-MS analysis obtained in the positive 
mode (A) and  in the negative mode (B) from CONT group. Representation of the zone of each PL class 
elutes and the mode carried out for the analysis.  
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5.3.1. Evaluation of Phosphatidylcholine Profile in Mitochondria 
 
 PCs are the most abundant phospholipids found in cell membranes and play an 
important role in mantaining the membrane structure. PCs ionize preferentially in the 
positive mode, forming [MH]
+
. In Figure 22, it is shown HPLC-MS spectra obtained for 
PC class of total lipid extract in control and cachexia conditions. The identification of 
PCs as well as their fatty acyl chains composition along the glycerol backbone was 
achieved by ESI-MS and interpretation of ESI-MS/MS spectra of each ion identified in 
the MS spectra, as resumed in Table 3. We were able to identify not only diacyl species, 
but also alkylacyl species. Diacyl and alkyl-acyl species of phospholipids with the same 
fatty acid compositions but are characterized by a mass difference of 14 Da, due to their 
attachment to the glycerol backbone of phospholipid by  ether or ester bonds (Figure 21).  
 
 
 
 
 
Figure 21: Alkylacyl (A) and diacyl (B) phospholipid structures. R represents the headgroup and R1 an 
R2 represent the fatty acid chain attached to the sn-1 and sn-2 positions respectively. 
 
By the analysis of MS spectra of PC (Figure 22) we can verified that the profile of 
PC molecular species are the same in the control and cachexia although the PC class 
relative content increase with cancer-related cachexia according to TLC  analysis. The 
HPLC-MS spectra of PC show major ions at m/z 758.7 (PC 16:0/18:2; 16:1/18:1), 782.7 
(16:0/20:4), and 806.7 (18:2/22:6) (Figure 22). By comparison of profiles in CONT and 
BBN, there is a slightly increase of the ion at m/z 806.7 (18:2/22:6) and at m/z 734.6 
(16:0/16:0). Increased PC(C18:2/22:6) is in accordance with the increase of longer fatty 
acid chains observed in GC-FID analysis.  
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Figure 22: General structure of Phosphatidylcholine (PC) (A); HPLC-MS spectra of PC class in the 
positive mode with formation of [MH]
+
 ions (B) in control (CONT) and (C) in cachexia situations (BBN). 
Y-axis: Relative abundance considering the highest abundant ion as 100 %; X-axis: m/z for each ion. 
*737.6 peak correspondent to the eluent. 
 
Table 3: Identification of the [MH]
+
 ions observed in the HPLC-ESI-MS spectra  PC. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bonds. 
P
h
o
sp
h
a
ti
d
y
lc
h
o
li
n
e 
(P
C
) 
 
Diacyl Species 
[MH]
+ 
m/z Molecular Species 
(C:N) 
Fatty Acyl Chains 
732.6 32:1 16:0/16:1 
734.6 32:0 16:0/16:0 
758.7 34:2 
16:0/18:2 
16:1/18:1 
760.7 34:1 16:0/18:1 
780.7 36:4 
16:1/20:4 
18:1/18:3 
782.7 36:4 16:0/20:4 
 
(A) 
(B) 
(C) 
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Table 3: Continued. 
P
h
o
sp
h
a
ti
d
y
lc
h
o
li
n
e 
(P
C
) 
 
Diacyl Species 
[MH]
+ 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
784.7 36:3 18:1/18:2 
786.7 36:2 18:0/18:2 
806.7 40:8 18:2/22:6 
808.7 38:5 18:1/20:4 
810.7 38:4 18:1/20:3 
814.7 38:2 
16:1/22:1 
18:1/20:1 
834.7 40:6 18:0/22:6 
Alkylacyl Species 
718.6 32:1 O-16:0/16:1 
746.7 34:1 O-16:0/18:1 
 
 
PC fragmentation in the MS/MS allowed to identify the fatty acyl composition of PC 
species. MS/MS spectra of [MH]
+
 ions of PC, is characterized by the loss of the 
headgroup phosphocholine (m/z 184), not observed in the MS/MS spectra acquired in the 
ion trap mass spectrometers,  loss of the head group (loss of 183) and the loss of the fatty 
acids as carboxylic acids ([M+H-R1COOH]
+
) [128, 156] (Figure 23). 
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[M+H-RCOO]
-
 
[M-H-183]+ 
[M+H-RCOO]
-
 
[M+H-RCOO]
-
 
 
 
 
 
 
 
 
Figure 23: Characteristic fragmentation of PC in the positive mode (A); HPLC-ESI-MS/MS spectrum of ion 
at m/z 758 corresponding to PC 16:0/18:2 and PC 16:1/18:1 mixture in the positive mode (B). Ions at m/z 
502,5; 478,4; 476,6 correspond to the loss of the fatty acid 16:0, 18:2 and 18:1 as a carboxylic acid ([M-H-
RCOOH]-), ion at m/z 575.5 corresponds to the loss of the phosphocholine headgroup. 
 
5.3.2. Evaluation of Sphingomyelin Profile in Mitochondria 
 
 As PC, SM species are choline-containing species, which ionize in positive mode as 
[MH]
+
. The HPLC-MS spectra obtained for SM is presented in Figure 24 and the 
identification of the [MH]
+
 ions resumed in Table 4. Since sphingomyelin class has an 
additional nitrogen atom they exhibit odd m/z values, in contrast with PC that showed 
even m/z values.  
 Analyzing SM spectra (Figure 24), it is possible to see that both are similar, thus 
indicating that no changes in SM molecular profile occurred after BBN administration. 
The HPLC-MS spectra of SM shows that the most abundant ion identified was at m/z 
731.7 (d18:1/18:0), followed by the ion at m/z 701.7 (d18:1/16:1) for control and 703.6 
(d18:1/16:0) for cancer-related cachexia situations, which corresponds to the unique 
alteration in both profiles. Since SM elutes close to PC class and given that in total lipid 
extract PCs are present in high amount, it was possible to identify in SM spectra some 
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PCs molecular species at m/z 758.6 and 782.6. However, the SM species formed as odd 
value of m/z allows us to differentiate between PCs and SMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: General structure of Sphingomyelin (SM) (A); HPLC-MS spectra of SM class in the positive 
mode with formation of [MH]
+
 ions (B) in control (CONT) and (C) in cachexia situations (BBN). Y-axis: 
Relative abundance considering the highest abundant ion as 100 %; X-axis: m/z for each ion. *737.6 peak 
correspondent to the eluent. 
 
Table 4: Identification of the [MH]
+
 ions observed in the HPLC-ESI-MS spectra of SM. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bounds. 
 
S
p
h
in
g
o
m
y
el
in
 
(S
M
) 
 
[MH]
+ 
m/z Molecular Species 
(C:N) 
Fatty Acyl Chains 
(Sphingoid base/Acyl) 
701.7 34:2  d18:1/16:1 
703.6 34:1 d18:1/16:0 
725.7 36:4 d18:1/18:3 
731.7 36:1 d18:1/18:0 
 
(A) 
(B) 
(C) 
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Table 4: Continued. 
 
[MH]
+ 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
(Sphingoid base/Acyl) 
733.6 36:0 d18:0/18:0 
753.7 38:4 d18:0/20:4 
759.7 38:1 d18:1/20:0 
761.7 38:0 d18:0/20:0 
787.6 40:1 d18:1/22:0 
813.6 42:2 d18:1/24:1 
815.6 42:1 d18:1/24:0 
 
 
 
5.3.3. Evaluation of Lysophosphatidylcholine Profile in Mitochondria 
LPCs were not detected in the TLC plate due to its very low abundance; however we 
were able to identify in the HPLC-MS spectra molecular species of this PL class. The 
molecular species of LPC class were analyzed in the positive ion mode, with formation of 
[MH]
+
 ions. The HPLC-MS spectra are shown in Figure 25 and the identification of the 
molecular species are resumed in Table 5. 
 Examining the LPC profiles obtained (Figure 25) we observe differences among 
them. The most prominent ion is the one at m/z 538.5 (O-20:4) corresponding to the main 
ion in the BBN situation. Also the ions at m/z 496.5, 522.5, 524.5, 546.5 and 560.5, 
corresponding to LPC(16:0), LPC(18:1), LPC(18:0), LPC(20:3), LPC(O-22:2), are increase 
in BBN situation. 
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Figure 25: General structure of Lysophosphatidylcholine (LPC) (A); HPLC-MS spectra of LPC class in the 
positive mode with formation of [MH]
+
 ions (B) in control (CONT) and (C) in cachexia situations (BBN). 
Y-axis: Relative abundance considering the highest abundant ion as 100 %; X-axis: m/z for each ion. 
*511.4  peak corresponds to an not identifiable specie. 
 
 
Table 5: Identification of the [MH]
+
 ions observed in the HPLC-ESI-MS spectra of LPC. Fatty 
acyl composition was attributed by the analysis of MS/MS spectra. C:N – number of carbons in 
the chain : number of double bonds. 
L
y
so
p
h
o
sp
h
a
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d
y
lc
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e
 
(L
P
C
) 
Diacyl Species 
[MH]
+ 
m/z 
Molecular Species 
(C:N) 
496.5 16:0 
522.5 18:1 
524.5 18:0 
546.5 20:3 
  
(A) 
(B) 
(C) 
Chapter III 
 ____________________________________________________________________________  
 
 
58 
 
Table 5: Continued. 
 
Alkylacyl Species 
[MH]
+ 
m/z 
Molecular Species 
(C:N) 
538.5 O-20:4 
560.5 O-22:2 
 
  
 
5.3.4. Evaluation of Phosphatidylethanolamine Profile in Mitochondria 
   The molecular species of PE class were analyzed in the negative mode, with the 
formation of [M-H]
-
 ions. The PE profile spectra of control and BBN are shown in Figure 26 
and the identification of [M-H]
-
 ions are resumed in Table 6. The identification of PE class 
spectra was confirmed by neutral loss map of 141 Da in the MS/MS acquired  in the positive 
mode and allow to identify diacyl and alkylacyl species as summarized in table 6. 
 By analysis of MS spectra of PE (Figure 26) we can observe differences between 
both conditions studied. The most abundant ion identified was at m/z 790.5 PE(18:0/22:6; 
18:1/22:5), followed by the ion at m/z 746.6 PE(18:0/18:0) and 774.6 PE(O-18:0/22:6), 
respectively. Interestingly the ion  at m/z 762.6 PE(16:0/22:6) was higher in comparison 
with the one at m/z 746.6 PE(18:0/18:0) in BBN situation. Higher PE with longer fatty acyl 
chains, namely PE(16:0/22:6) are in accordance with augment in longer fatty acid analysis. 
On the other hand, the ion at m/z 746.6 PE(18:0/18:0) is also in accordance with the fatty 
acid profile that showed decrease in C18:0. 
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Figure 26: General structure of Phosphatidylethanolamine (PE) (A); HPLC-MS spectra of PE class in the 
negative mode with formation of [M-H]- ions (B) in control (CONT) and (C) in cachexia situations (BBN). 
Y-axis: Relative abundance considering the highest abundant ion as 100 %; X-axis: m/z for each ion. 
*737.6 peak correspondent to the eluent. 
 
Table 6: Identification of the [M-H]
-
 ions observed in the HPLC-ESI-MS spectra of PE. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bonds. 
P
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(P
E
) 
Diacyl Species 
[M-H]
- 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
700.6 34:2 
16:0/18:2 
16:1/18:1 
714.6 34:2 
16:0/18:2 
16:1/18:1 
716.6 34:1 16:0/18:1 
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Table 6: Continued. 
 
740.4 36:3 18:1/18:2 
742.5 36:2 
18:0/18:2 
18:1/18:1 
744.6 36:1 18:0/18:1 
746.6 36:0 18:0/18:0 
762.6 38:6 16:0/22:6 
764.5 38:5 18:1/20:4 
766.5 38:5 18:0/20:4 
768.5 38:3 18:1/20:2 
770.4 38:2 18:0/20:2 
772.5 38:1 18:0/20:1 
790.5 40:6 
18:0/22:6 
18:1/22:5 
792.5 40:5 18:0/22:5 
794.4 40:4 18:0/22:4 
798.4 40:2:00 18:0/22:2 
Alkylacyl Species 
774.5 40:6 O-18:0/22:6 
750.5 38:4 O-18:0/20:4 
778.5 40:4 O-18:0/22:4 
 
 
 
Carboxylate anions ([RCOO]-) are detected through the fragmentation of PE in the 
negative mode. Neutral loss of the fatty acids as carboxylic acids ([M-H-RCOOH]-) in 
combination with the carboxylate anions allow the characterization of the fatty acids 
present in the PE molecular species [128, 156] (Figure 27). 
  
III. Results 
 ____________________________________________________________________________  
 
 
61 
 
[R2COO]
- 
[R1COO]
- 
  
 
 
 
 
 
  
 
 
 
Figure 27: Characteristic fragmentation of PE in the  negative mode (A); HPLC-ESI-MS/MS spectrum of 
ion at m/z 790 corresponding to PE 18:0/22:6 and PE 18:1/22:6 in the negative mode  (B). Ions at m/z 283; 
327 and 329 correspond to the carboxylate ions ([RCOO]
-
) of the 18:0, 22:6 and 22:5 fatty acids respectively. 
Ion at m/z 462 corresponds to the loss of the fatty acid 20:0 as a carboxylic acid ([M-H-RCOOH]
-
), and ion at 
m/z 480 corresponds to the loss of the fatty acid as ketene. 
 
 
5.3.5. Evaluation of Phosphatidylserine Profile in Mitochondria 
 
 PS species were also analyzed in the negative mode that allowed the formation of 
[M-H]
-
 ions. The MS spectra obtained for PS  are shown in Figure 28 and PS species 
identified are resumed in Table 7. The identification of PS class was confirmed by MS/MS 
that showed the loss of the head group serine with formation of the product  ion [M-H-87]
-
 
and [M-H-87-RCOOH]
-
, corresponding to the neutral loss of the serine and subsequent 
loss of the fatty acid.  Analyzing HPLC-MS spectra of PS (Figure 28) we can identified 
the ion at m/z 790.5, PS (18:0/18:0) as the most abundant specie, followed by the ion at m/z 
834.5 PS(18:0/22:6) for control and 828.4 PS(18:3/22:6) for cancer-related cachexia 
situations. This profile is once again according with increased longer fatty acid chains 
relative content with GC-FID analysis. 
  
[M-H-R2COO]
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[M-H-R2CH=C=O]
-
 
[R2COO]
- 
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Figure 28: General structure of Phosphatidylserine (PS) (A); HPLC-MS spectra of PS class in the negative 
mode with formation of [M-H]
-
 ions (B)  in control (CONT) and (C) in cachexia situations (BBN). Y-axis: 
Relative abundance considering the highest abundant ion as 100 %; X-axis: m/z for each ion. 
Table 7:  Identification of the [M-H]
-
 ions observed in the HPLC-ESI-MS spectra of PS. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bonds. 
PS 
[M-H]
- 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
790.5 36:0 
18:0/18:0 
828.4 40:9 
18:3/22:6 
834.5 40:6 
18:0/22:6 
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5.3.6. Evaluation of Phosphatidylinositol Profile in Mitochondria 
 
 The molecular species of PI class were analyzed in the negative ion mode, with the 
formation of [M-H]
-
 ions. The PI profile spectra are presented in Figure 29 and the 
identification of the [M-H]
-
 ions resumed in Table 8. The identification of PI class in MS 
spectrum was confirmed by MS/MS that showed neutral loss of fatty acyl species 
combined with loss of inositol (-162 Da).  
 The analysis of PI spectra allow us to identify four major [M-H]
-
 ions observed at m/z 
861.6, 885.6, 887.5 and  909.6 and, corresponding to PI(18:0/18:2), PI(18:0/20:4), 
PI(18:0/20:3) and PI(18:0/22:6) . Although analysis of phospholipid content showed a 
slight decrease in the relative content of PI class, no differences were observed in the MS 
spectra of control and cachexia situations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: General structure of Phosphatidylinositol (PI) (A); HPLC-MS spectra of PI class in the negative 
mode with formation of [M-H]
-
 ions (B) in control (CONT) and (C) in cachexia situations (BBN). Y-axis: 
Relative abundance considering the highest abundant ion as 100%; X-axis: m/z for each ion. 
(A) 
(B) 
(C) 
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Table 8: Identification of the [M-H]
-
 ions observed in the HPLC-ESI-MS spectra of PI. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bonds. 
PI 
[M-H]
- 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
861.6 36:2 
18:0/18:2 
885.6 38:4 
18:0/20:4 
887.5 38:3 
18:0/20:3 
909.6 40:6 
18:0/22:6 
 
 
 
5.3.7. Evaluation of Phosphatidylglycerol Profile in Mitochondria 
PG molecular species were also analyzed in the negative mode, with the formation of 
[M-H]
-
 ions. The MS spectra of PG class are presented in Figure 30 and the identification 
of the [M-H]
-
 ions  resumed in Table 9. Also in this class (as we can see in Figure 30) the 
differences between the two spectra are not significant despite the decrease showed by 
phospholipids relative content quantification. 
Analyzing HPLC-MS spectra of PG (Figure 30), we can identified the ion at m/z 
747.6 (16:0/18:1) as the most abundant, followed by the ion at m/z 773.6 (18:1/18:1; 
18:0/18:2) and 775.6 (18:0/18:0). No differences between control and BBN situations are 
observed in PG profile. 
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Figure 30: General structure of Phosphatidylglycerol (PG) (A); HPLC-MS spectra of PG class in the 
negative mode with formation of [M-H]
-
 ions (B) in control (CONT) and (C)  in cachexia situations (BBN). 
Y-axis: Relative abundance considering the highest abundant ion as 100%; *737.6 peak correspondent to 
the eluent. 
 
Table 9: Identification of the [M-H]- ions observed in the HPLC-ESI-MS spectra of PG. The 
identification of the fatty acyl composition was done according to the interpretation of the 
correspondent MS/MS. C:N – number of carbons in the chain : number of double bonds. 
PG 
[M-H]
- 
m/z 
Molecular Species 
(C:N) 
Fatty Acyl Chains 
747.6 34:1 16:0/18:1 
773.6 36:2 
18:1/18:1 
18:0/18:2 
775.6 36:1 18:0/18:0 
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5.3.8. Evaluation of Cardiolipin Profile in Mitochondria 
The molecular species of CL class were analyzed in the negative ion mode. This 
phospholipid has four alkyl groups and ionize with the formation of [M-H]
-
 or [M-2H]
2-
 
ions (mono or double charge species). The CL profile spectra are presented in Figure 31. 
The analysis was achieved by direct interpretation of MS/MS spectra of each ion identified 
in the MS spectra, both [M-H]
-
 and [M-2H]
2-
. By analysis of MS spectra (Figure 31), we 
can identify only one ion [M-H]
-
 at m/z 1447.8 corresponding to CL(18:2/18:2/18:2/18:2). 
No differences were observed between the MS spectra from the two studied conditions.
 
 
 
 
 
 
 
Figure 31: General structure of Cardiolipin (CL) (A); HPLC-MS spectra of CL class in the negative mode 
with formation of [M-H]
-
 ions (B) in control (CONT) and (C) in cachexia situations (BBN). Y-axis: 
Relative abundance considering the highest abundant ion as 100%; 
 
The MS/MS spectra of the  [M-H]
-
 ions allows the structural characterization of CL and 
can be divided in three distinct zones, as described by Hsu and Turk [157]: the 
phosphatidic acid [PA-H]
-
, m/z 695; the [(PA-H)+136]
-
, m/z 831 and the mono 
phosphatidic with loss of the fatty acyl chains ([PA-RCOOH]
-
), m/z 415, as it is 
schematically represented in Figure 32. By MS/MS spectra of the  [M-2H]
2-
 ions we can 
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achieved the structure of the product ions resulting from the fragmentation CL [M-2H]
2 
(Figure 32C) with the product ions [(M-2H)-RCOO
-
]
-
, at m/z 1167, formed by the loss of 
fatty acyl anion and the double charged ion [M-2H-R=C=O]
2-
, at m/z 592, formed by the 
loss of fatty acyl as ketene. Other abundant product ions are the carboxylate anions, 
RCOO
-
, observed at m/z 279, the [M-H]
- 
ions of phosphatidic acid (PA), at m/z of 695. 
The ion at m/z 415 is also visible and corresponds to the loss of RCOOH from the 
phosphatidic acid (PA), with formation of the ion [PA-RCOOH-H]
-
. In this spectrum we 
can also observe similar fragmentation pathways as previously described by Hsu and 
Turk [157]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Typical CL fragmentation products and CL molecular structure (A); HPLC-ESI-MS/MS 
spectrum of the [M-2H]
2-
  ion at m/z 723 corresponding to CL (18:2)4 in the negative mode (B); HPLC-ESI-
MS/MS spectrum of the [M-H]
-
  ion at m/z 1447 corresponding to CL (18:2)4 in the negative mode (C).  
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IV. Discussion 
 
 Cancer cachexia (CC) is a complex pathophysiological condition related to 
increased morbidity and mortality in cancer patients [1]. Since the poor quality of life and 
intolerance to treatment is related to muscle wasting, it is needed a better understand of the 
molecular mechanisms underlying cancer-induced skeletal muscle wasting [10]. In order 
to mimic cancer cachexia and its complications, a well characterized animal model of 
bladder cancer was used.  For this purpose, Wistar rats were subjected to N-butyl-N-(4-
hydroxybutyl)-nitrosamine (BBN) oral administration for 20 weeks followed by 8 weeks 
of tap water consumption. The loss of 17% body weight and 12% muscle mass evidenced 
by animals with notorious bladder nodular hyperplasia confirmed the occurrence of 
cachexia (Table 1). Additionally, mitochondria isolated from gastrocnemius muscle seem 
less functional in cachectic animals considering the decreased activity of OXPHOS 
complexes II and V (Table 2). These results are supported by the decreased expression of 
ATP synthase β evaluated by western blotting analysis, which synthesis impairment has 
been related in skeletal muscle wasted conditions [21, 158]. Also the lower levels of 
cytochrome c observed in mitochondria from animals with urothelial carcinoma might be 
related to decreased electron transporter function (Figure 10). Furthermore, the decreased 
expression of ETFβ and ETFDH might be associated to mitochondrial respiratory chain 
impairment considering their function as electron carrier in the respiratory chain [60]. 
Indeed, ETF transfers electrons to ubiquinone in the mitochondrial respiratory chain [60]. 
The decreased oxidative activity was paralleled by the accumulation of oxidatively 
modified proteins in BBN-induced cachexia, specifically carbonylated proteins, which has 
been associated with impaired cellular function in aged muscle [101, 159]. These data 
seem to reflect greater susceptibility to oxidative modifications in cancer cachexia, which 
are consistent with the association between mitochondrial dysfunction and oxidative 
damage to proteins [66].   
Taken together, our data suggest the accumulation of dysfunctional mitochondria in 
the gastrocnemius of cachectic animals. Indeed, mitochondrial dysnfunction has been 
recently suggested in cancer-related muscle wasting; however the mechanisms involved 
are not fully elucidated [21].  Moreover, UCP-3 an uncoupling protein was found in 
increased levels in the skeletal muscle mitochondria of BBN animals (Figure 11C). This 
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protein forms a channel in the inner mitochondrial membrane that allows protons to reenter 
the mitochondrial matrix without passing through the ATP synthase complex, leading to 
uncoupling of ATP synthesis rate [72]. An important role in fatty acid transport for further 
oxidation in situations of increased supply of fatty acids has been attributed to UCP-3 in 
skeletal muscle, since most part of ATP is generated via fatty acid oxidation [101]. In this 
way, the overexpression of this protein might be related not only with the diminished 
OXPHOS activity but also with changes in the phospholipid profile, with the increase of 
metabolites from the glycosphingolipid pathway and PC, and reduction of metabolites 
content from the glycerophospholipid pathway, PG, PA and CL (Figures 16 and 17). The 
general phospholipid composition of rat gastrocnemius muscle was similar to that reported 
for this and other skeletal muscles of the same or different species [116]: PC and PE were 
the prominent species, by far exceeding the rest (Figure 16).  No significant alterations of 
PE relative content were verified. Bӧttinger et al. [160] suggested that PE plays an 
important role for mitochondrial functionality, given the decreased cyt c activity when PE 
levels were decreased. Phosphatidylserine (PS) similarly to CL has been related to 
oxidative damage and apoptosis, these alterations are leading by exposure on the outer 
leaflet of the membrane in a process so-called PS externalization [85].  Finally, regarding 
phosphotidylinositol (PI), no oxidation products in mitochondria of gastrocnemius muscle 
were found after BBN administration, though this phospholipid contains polyunsaturated 
potentially oxidizable species [133].  Concomitantly, significant lower levels of PG and CL 
were observed in BBN-related muscle wasting. Their decrease seem to affect electron 
transfer efficiency and mitochondrial energy production, taking into account the 
mitochondrial membrane phospholipids functions. Furthermore, the decreased expression 
of cytochrome c appears to be  correlated with cytochrome c peroxidase activity and 
oxidataion of cardiolipin [88]. Indeed, lower levels of this protein were detected in 
mitochondria from gastrocnemius of BBN rats (Figure 10A), which together with PL 
profile alterations highlight the implications of the disruption of specific protein-lipid 
interactions for the appropriate performance of mitochondria. Oxidation of CL by cyt c is 
associated with the release of cyt c to the cytosol and also associated to loss of CL content. 
In addition, the loss of CL content has been related with mitochondrial dysfunction, 
increased membrane permeability and impair respiratory rate also due to its association 
with complexes I, III, IV and V for their optimal activity [80, 85].  
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Lipid peroxidation has been hypothesized to be associated to mitochondrial 
dysfunction [81, 124] and CL comprises a vulnerable target of this oxidative damage due 
to their high content of unsaturated fatty acids, namely linoleic acid and docosahexaenoic 
acid [80]. However, no oxidation products of CL were observed. This could be due to loss 
of oxidized CL because of UCP3 activation. In fact UCP3 is activated by lipid 
hydroperoxides and is involved in mediating the translocation of LOOH across the 
mitochondrial membrane and in LOOH-dependent mitochondrial uncoupling [161]. It has 
been suggested that higher levels of UCP-3 were able to protect mitochondria from ROS 
and by eliminate or extrude lipid hydroperoxides. UCP3 has been also suggested as 
responsable by exporting LOOH to outer mitochondrial matrix. This effect may protect 
mitochondria from lipid damage, but on the other side, may affect membrane properties in 
consequence of changes in the PL relative content which can affect protein assembly and 
function [161]. However, mitochondrial proteins were not protect from the oxidative 
damage once we verified an increase of carbonylated proteins (Figure 12). In fact, the 
accumulation of carbonylated mitochondrial proteins has also been associated with 
impaired respiratory function [65], playing a crucial role in the pathogenesis of cancer-
related cachexia. Since skeletal muscle is multi-nucleated along with the high 
concentration of endogenous apoptosis inhibitor molecules, apoptosis occur under some 
conditions such as skeletal muscle atrophy [162]. Additionally, the decreased functionality 
of mitochondria (Table 2) seems related to greater susceptibility to apoptosis as previously 
suggested [68].  In fact, an increase of the Bax/Bcl-2 ratio was observed in BBN 
mitochondria. In apoptotic processes, caspases are the main enzymes involved in the 
initiation and execution of apoptosis and the balance between pro- and anti-apoptotic 
proteins of Bcl-2 family can control caspases activation. Bax is pro-apoptotic and Bcl-2 
anti-apoptotic. An imbalance in this shift results in the release of the pro-apoptotic factor 
cytochrome c [95], validating the decreased cytochrome c levels observed. The decreased 
levels of CL (Figure 15) also contribute to cyt c release, since the interaction between both 
is required for cytochrome c attachment and also for an efficient respiratory activity [80, 
85, 160].  This release leads to radical species production that could accelerate apoptotic 
processes [92, 160]. 
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V. Conclusions 
 
In order to elucidate the molecular mechanisms underlying cancer-induced muscle 
wasting in skeletal muscle, 23 Wistar rats were randomly divided in two groups: animals 
with bladder cancer induced by the administration of N-butyl-N-(4-hydroxybutyl)-
nitrosamine for 20 weeks (BBN, n=13) or healthy ones (CONT, n=10) and mitochondria 
were isolated from gastrocnemius muscle and biochemically analyzed. Data obtained 
allowed to conclude that: 
i. Urothelial carcinoma induced by BBN administration resulted in a 17% decrease of 
body weight and 12% of muscle mass as compared to healthy animals. The activity 
of respiratory chain complexes II and V diminished and was accompanied by 
decreased expression of metabolic proteins. 
ii. The increased susceptibility of mitochondrial proteins to carbonylation seems to 
justify, at least partially, the mitochondrial dysfunction underlying muscle wasting. 
iii. Decreased OXPHOS activity of gastrocnemius muscle was parallel to PL profile 
remodelling characterized by higher PC levels, lower PG, PA and CL content and 
increased degree of unsaturation of fatty acyl chains. 
iv. Skeletal muscle from BBN animals seem more susceptibility to apoptosis, 
represented by decreased cytochrome c expression levels, increased Bax/Bcl-2 ratio 
and decreased CL content.  
v. The decreased CL content may be responsible for the decrease in cyt c activity and 
thus affect mitochondria functionality. 
vi. Higher levels of UCP-3 seem to protect mitochondrial from lipid mediated 
oxidative damage since no MS evidences of lipid peroxidation and TBARS levels 
were observed between groups. 
 
 
Taken together, urothelial carcinoma induced by BBN administration resulted in 
muscle wasting due to mitochondrial dysfunction, which was underlied by PL remodeling 
with higher content of long fatty acyl side chains, accumulation of oxidized mitochondrial 
proteins that ultimately might lead to muscle apoptosis. Future work focused on 
therapeutic strategies to counteract cancer-related muscle wasting will be crucial aiming to 
improve patients’ quality of life. 
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